Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps by Rolf Teschke & Axel Eickhoff
REVIEW
published: 23 April 2015
doi: 10.3389/fphar.2015.00072
Frontiers in Pharmacology | www.frontiersin.org 1 April 2015 | Volume 6 | Article 72
Edited by:
Jia-bo Wang,
302 Military Hospital of China, China
Reviewed by:
Hong Yang,
Liaoning Normal University, China
Jia-bo Wang,
302 Military Hospital of China, China
Ji-dong Jia,
Beijing Friendship Hospital, China
*Correspondence:
Rolf Teschke,
Division of Gastroenterology and
Hepatology, Department of Internal
Medicine II, Klinikum Hanau,
Academic Teaching Hospital of the
Goethe University of Frankfurt/Main
Leimenstrasse 20, D-63450 Hanau,
Germany
rolf.teschke@gmx.de
Specialty section:
This article was submitted to
Ethnopharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 19 January 2015
Paper pending published:
10 February 2015
Accepted: 18 March 2015
Published: 23 April 2015
Citation:
Teschke R and Eickhoff A (2015)
Herbal hepatotoxicity in traditional and
modern medicine: actual key issues
and new encouraging steps.
Front. Pharmacol. 6:72.
doi: 10.3389/fphar.2015.00072
Herbal hepatotoxicity in traditional
and modern medicine: actual key
issues and new encouraging steps
Rolf Teschke* and Axel Eickhoff
Division of Gastroenterology and Hepatology, Department of Internal Medicine II, Klinikum Hanau, Academic Teaching
Hospital of the Medical Faculty of the Goethe University Frankfurt Main, Frankfurt, Germany
Plants are natural producers of chemical substances, providing potential treatment of
human ailments since ancient times. Some herbal chemicals in medicinal plants of
traditional and modern medicine carry the risk of herb induced liver injury (HILI) with
a severe or potentially lethal clinical course, and the requirement of a liver transplant.
Discontinuation of herbal use is mandatory in time when HILI is first suspected as
diagnosis. Although, herbal hepatotoxicity is of utmost clinical and regulatory importance,
lack of a stringent causality assessment remains amajor issue for patients with suspected
HILI, while this problem is best overcome by the use of the hepatotoxicity specific
CIOMS (Council for International Organizations of Medical Sciences) scale and the
evaluation of unintentional reexposure test results. Sixty five different commonly used
herbs, herbal drugs, and herbal supplements and 111 different herbs or herbal mixtures
of the traditional Chinese medicine (TCM) are reported causative for liver disease, with
levels of causality proof that appear rarely conclusive. Encouraging steps in the field
of herbal hepatotoxicity focus on introducing analytical methods that identify cases of
intrinsic hepatotoxicity caused by pyrrolizidine alkaloids, and on omics technologies,
including genomics, proteomics, metabolomics, and assessing circulating micro-RNA
in the serum of some patients with intrinsic hepatotoxicity. It remains to be established
whether these new technologies can identify idiosyncratic HILI cases. To enhance its
globalization, herbal medicine should universally be marketed as herbal drugs under
strict regulatory surveillance in analogy to regulatory approved chemical drugs, proving a
positive risk/benefit profile by enforcing evidence based clinical trials and excellent herbal
drug quality.
Keywords: herb induced liver injury, hepatotoxicity, herbal hepatotoxicity, herbs, evidence based trials, herbal
traditional Chinese medicine, herbal modern medicine, herbal traditional medicine
Introduction
Ancient Chinese and Egyptian papyruses describe medicinal use of plants for various ailments
as early as 3.000 BC and thereby long before recorded history (Major, 1954; IARC Monographs,
2002). Starting at around that time, herbal traditional medicine originating from Mesopotamia,
Egypt, and India influenced Byzantine, Greek, Latin, and Indian herbal medicine, thereby establish-
ing principles of Ayurveda in India and developing traditional occidental herbal medicine, which
subsequently became popular in numerous European and other Western countries (Major, 1954;
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IARC Monographs, 2002; Raghavendra et al., 2009; NIH, 2013).
Indigenous cultures such asAfrican,NorthAmerican,Middle and
South American, Australian, and South Pacific islandic also used
herbs in their healing rituals (IARCMonographs, 2002). In other
parts of the world, herbal traditional Chinese medicine (TCM)
emerged (IARC Monographs, 2002; Raghavendra et al., 2009)
and influenced the traditional Oriental herbal medicine in Japan
(IARC Monographs, 2002), called Kampo medicine (Nishimura
et al., 2009), and other Asian countries such as Korea with its
herbal traditional Koreanmedicine (Park et al., 2012).With TCM
originating in China and Ayurveda in India, twomost ancient yet
living traditions of herbal medicine presently remain and expe-
rience some extension over the globe (Patwardhan et al., 2005).
Although, most other ancient herbal medicine cultures vanished
or are restricted to local use without potential globalization, many
countries use herbal medicines (WHO, 2002, 2013).
The worldwide use of medicinal herbs has increased over
the past years (WHO, 2002, 2013; Ekor, 2014), but their reg-
ulatory surveillance differ among countries due to lack of har-
monization (WHO, 2005; Ekor, 2014). The world market for
herbal medicines based on traditional knowledge is estimated at
US$60,000 million annually (WHO, 2002), according to a UN
report dating back to 2000 (UN, 2000). Alone in the United
States, the total estimated herb retail sales in all channels rose
from $4230million in 2000 to $6032million in 2013, correspond-
ing to 42.6% overall and to 3.3% on an annual basis according
to the data of the American Botanical Council (Lindstrom et al.,
2014). These figures compare to the increased use of comple-
mentary and alternativeMedicine (CAM), since an estimated $27
billion was spent by consumers of CAM in the United States in
1997 (Eisenberg et al., 1998) and $33.9 billion in 2007 (Nahin
et al., 2009), equaling a rise of 25.5%. These figures considered
all CAM related expenditures spent out of pocket on visits to
CAM practitioners and purchases of CAM products, classes, and
materials in the United States in 2007, with $14.5 billion spent on
the purchase of nonvitamin, nonmineral, and natural products
(Nahin et al., 2009); the widespread use of herbal medicine exerts
a high economic power in our society with special financial ben-
efits for herb producers, providers, and healers. Considering this
enormous economic impact and the resulting expenditures, the
question is whether these high costs as burden for the consumers
and the society are warranted. In addition, herbal medicine is
increasingly exposed to major pressure due to concerns of effi-
cacy, safety (NIH, 2014a), and adverse reactions (Podsadzki et al.,
2013; Ekor, 2014) such as liver injury (NIH, 2014a).
In this review article, we critically analyze actual key issues of
herbal hepatotoxicity by herbal products of traditional and mod-
ern medicine and discuss future developments. The expressions
of herbal hepatotoxicity and herb induced liver injury (HILI) are
used synonymously. Some similarities of HILI exist with DILI
(drug induced liver injury) (Teschke et al., 2013f).
Methods
Data Sources and Searches
We used the PubMed to identify publications on herbal hepato-
toxicity and HILI which each provided hits of around 279.000
and 1.840.000. Our search was then further qualified and
extended using additional keywords denoting herbal modern
medicine and herbal TCM, providing additional hits. The first
100 hits of publications in each category were considered.
Study Selection
The focus of our search was on publications in English language,
but relevant reports of other languages also were considered.
The retrieved publications included case reports, case series and
review articles and were analyzed whether they were appropriate
and relevant for the topic of this article. Publications also were
manually searched for additional publications not yet identified.
Data Extraction and Quality Assessment
Prior to our analysis, the publications were assessed regarding
their scientific and clinical quality. Publications of relevance and
good quality were preferred and considered for evaluation.
Key Issues
Herbal products in traditional and modern medicine are com-
monly perceived by the general population as well tolerated and
devoid of major adverse reactions. One of the most important
goals in clinical practice is to offer patients an efficient therapy
for their ailment(s), without harming their health. However, effi-
cacy and safety by the use of herbs in traditional and modern
medicine are features that may apply to some herbs and patients
but certainly not to others. Similar shortcomings are known from
conventional chemical drugs, which also are not effective in all
patients. The risk of rare adverse reactions occurring in various
organs including the liver relates to both, herbs (NIH, 2014a) and
synthetic drugs (NIH, 2014b).
Hepatotoxicity Case Reports
General Aspects
Basic knowledge of hepatotoxicity by drugs and numerous other
chemicals was summarized by Hyman Zimmerman in his pio-
neering book 25 years ago, brieflymentioning already some herbs
as culprits and referencing a few case reports of herbal hep-
atotoxicity (Zimmerman, 1999). Since then, many more HILI
cases emerged, which previously were reported (Pittler and Ernst,
2003b) and recently analyzed in publications on herbal TCM
preparations (Teschke, 2014; Teschke et al., 2014c, 2015b), other
commonly used herbal products (Teschke et al., 2013f), and
herbal and dietary supplements (HDS) (Halegoua-De Marzio
et al., 2013; Teschke et al., 2013d; Navarro et al., 2014; Robles-
Diaz et al., 2015).
Epidemiology
Epidemiology data of hepatotoxicity cases in connection with
herbal use are crucial to assess, both in traditional and modern
medicine. Actually, the true prevalence of herbal hepatotoxicity
is the total number of HILI cases in the population at a given time
(Teschke et al., 2013f). It represents an estimate of how common
herbal hepatotoxicity is within a population and at a fixed time.
Conversely, the incidence of herbal hepatotoxicity is expressed
as the total number of new HILI cases during a certain period
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of time, divided by the number of individuals in the population
initially at risk. Therefore, incidence differs from prevalencemea-
suring new HILI cases; for chronic liver injury, these values may
change.
Incidence commonly provides information about the risk of
acquiring HILI, whereas prevalence signifies how widespread
HILI is. The true prevalence and incidence of HILI (Navarro,
2009) and HDS (Navarro et al., 2014; Robles-Diaz et al., 2015)
is unknown. Global epidemiology considerations of prevalence
and incidence refer to all herbs contained in herbal drugs and
herbal supplements, whereas specific epidemiology is restricted
to one single herb. Global epidemiology data therefore may be
used for health economy assessment whereas specific epidemi-
ology data pertain to herbal product safety. For this purpose,
true global prevalence and incidence of HILI still has to be deter-
mined through cohort studies or case control-studies, a difficult
approach. For an appropriate assessment of the risks from a spe-
cific herbal product, there is lack of quantitative data for con-
sumption of herbal products, number of HILI patients, and the
population at risk. In addition, herbal product authentication is
missing in most cases of suspected HILI and impedes causality
assessment for the incriminated herb (Teschke et al., 2013f). Case
underreporting and overdiagnosing also prevent determination
of the true incidence; future studies will have to address these
issues in order to provide firm data of prevalence and incidence
in HILI.
For DILI by synthetic drugs, respective data are available: the
estimated annual incidence rate of DILI at a coordinating center
in Spain was 34.2± 10.7 cases per 106 inhabitants (Andrade et al.,
2005), and in a French study it was 13.9 ± 9 per 106 inhabitants
per year (Sgro et al., 2002).
Compilation of Hepatotoxicity Cases
For herbal TCM with potential liver injury, we identified 44 dif-
ferent TCM herbs and 21 herbal TCM mixtures, published in
case reports and case series as provided by appropriate references
(Table 1). These referenced reports present clinical case details,
summarized in part also earlier (Teschke, 2014). The 12 most
common Chinese herbal medicines with hepatotoxicity detailed
in a recent review (Ma et al., 2014) are also included in the present
compilation (Table 1).
Other herbs and herbal products unrelated to TCM showed
reported potential hepatotoxicity for 111 items (Table 2), pre-
sented as an update of an earlier compilation (Teschke et al.,
2012h). Most of the actual 111 items identified single herbs,
rarely mixtures with HDS as examples with various ingredients
(Table 2). Numerous other HDS with assumed potential hepa-
totoxicity are listed in compilations of other reports published
just recently (Bunchorntavakul and Reddy, 2013; Navarro et al.,
2014; Robles-Diaz et al., 2015) and hence were not included in
the present compilation (Table 2).
In the past, some review articles focused exclusively on HILI
by TCM herbs and herbal preparations (Ma et al., 2014; Teschke,
2014; Teschke et al., 2014c, 2015b) as a primarily neglected topic,
which was otherwise considered as part of overall assessments
on herbal hepatotoxicity in few publications (Zimmerman, 1999;
Abdualmjid and Sergi, 2013; Bunchorntavakul and Reddy, 2013),
including an official and well updated NIH statement (NIH,
2014a).
Symptomatology
Clinical symptoms of herbal hepatotoxicity in traditional and
modern medicine are variable and described in published
case reports, case series, and regulatory presented spontaneous
reports as referenced (Tables 1, 2). Symptoms are mostly unspe-
cific and sometimes difficult to direct to the liver, which delays
early recognition of the unfolding liver injury (Teschke et al.,
2013f, 2014c; Ma et al., 2014). Clinical signs may emerge alone or
in combination with other features, while jaundice is the symp-
tom initially best recognized by the patient, facilitating the search
for advice by the primary care physician. In detail, patients with
herbal TCM hepatotoxicity experience fatigue (67.3%), jaundice
(60.3%), anorexia (58.0%), nausea (35.9%), and fever (19.3%),
but signs such as rash, pruritus, and pale stools have also been
reported (Ma et al., 2014). In another study of 16 cases of Greater
Celandine (GC) with established HILI, symptoms were present
in 15 cases (Teschke et al., 2012a). Single or multiple symptoms
were anorexia (n = 3), fatigue (n = 5), nausea (n = 6), vomiting
(n = 2), dyspepsia (n = 1), bloating (n = 1), abdominal discom-
fort (n = 1), right upper quadrant pains (n = 1), epigastric pains
(n = 1), unspecified abdominal pains (n = 1), fever (n = 1),
dark urine (n = 3), pale stool (n = 1), pruritus (n = 3), and
jaundice (n = 15) (Teschke et al., 2012a). For reasons of trans-
parency, narrative case details and clinical data of patients with
assumed HILI should be provided in tabular form, as done previ-
ously (Teschke et al., 2008a, 2011a, 2012a,b,d,e; Teschke, 2010a)
and shown for GC hepatotoxicity as example (Table 3). Detailed
information also allows characterization of HILI by a single herb
such as GC (Table 4).
Although, clinical features are quite similar in HILI cases by
traditional and modern medicine (Chau et al., 2011; Teschke
et al., 2013f; Ma et al., 2014), there is one exception that relates
to the hepatic sinusoidal obstruction syndrome (HSOS), for-
merly hepatic veno-occlusive disease (HVOD); this special liver
injury is caused by pyrrolizidine alkaloids (PAs) contained in var-
ious TCM herbs, with its major diagnostic features of abdominal
distension and pain, ascites, malaise, hepatomegaly, and body
weight gain due to ascites and edema caused by fluid accumu-
lation (Wang and Gao, 2014). Jaundice was most frequent with
84.8% in 100/118 cases of PA induced HSOS by Tu San Qi
(Gynura segetum), ascites with 99.2% (121/122 cases, and hep-
atomegaly with 92.0% (104/113 cases) (Lin et al., 2011; Gao et al.,
2012).
In a typical HILI case unrelated to PAs, the chronology of
symptoms may follow a particular stepwise pattern, as described
for HILI caused by Indian Ayurvedic herbs through an excellent
observation by a patient under treatment for her vitiligo (Teschke
and Bahre, 2009). Her symptoms started with pruritus, followed
by loss of appetite, fatigue, nausea, vomiting, dark urine, light
stool, until finally jaundice was recognized by her family physi-
cian; this sequence of symptoms stretched over almost 4 months
under continued herbal medication.
Patients with HILI may be asymptomatic with increased val-
ues observed by chance, monosymptomatic, or polysymptomatic.
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TABLE 1 | Compilation of reported cases with suspected hepatotoxicity by herbal traditional Chinese medicine (TCM).
Name with ingredients Cases (n) References
Ai Ye Artemisia argyi na Ma et al., 2014
An Shu Ling Lycopodium serratum or, rarely, Corydalis species, Panax ginseng, Pseudo ginseng, or two species of Stephania 1 Haller et al., 2002
Bai Fang Angelica sinensis, Cyperus rotundus, Ginseng, Ligusticum wallichii, Paeonia alba, Rehmannia glutinosa 1 Estes et al., 2003
Bai Shi Wan Atractylis, Carthamus tinctorius, Dalbergia odorifera, Dioscorea bulbifera, Glycyrrhiza, Lithospermum
erythrorhizon, Paeonia suffruticosa, Polygonum multiflorum, Psoralea corylifolia, Salvia miltiorrhiza; Endoconcha sepiae,
Ganoderma lucidum (mushroom)
1 Talari et al., 2010
Bai Xian Pi Dictamnus dasycarpus 1 Perharic-Walton and
Murray, 1992
1 Kane et al., 1995
1 Vautier and Spiller,
1995
2 Yuen et al., 2006
4 Jang et al., 2008
14 Kang et al., 2008
2 Sohn et al., 2008
Bi Ma Zi Rhicinus communis na Ma et al., 2014
Ban Tu Wan Angelica sinensis, Chaenomeles, Codonopsis pilosula, Notopterygium, Polygonum multiflorum, Rehmannia,
Schisandra
1 Cortez et al., 2012
Bo He Mentha haplocalyx
Bo Ye Qing Niu Dan Tinospora crispa 2 Sangsuwan et al., 2004
Bofu Tsu Sho San Angelica, Atractylis, Cnidium, Gardenia, Ephedra, Forsythia, Glycyrrhhiza, Gypsum fibrosum, Ledebouriella,
Mentha, Paeonia, Platycodon, Rheum, Schizonepeta, Scutellaria, Zingiber; Kadinum (talcum powder), sodium sulfuricum
1 Motoyama et al., 2008
Boh Gol Zhee Psoralea corylifolia 1 Hwang et al., 2001
1 Nam et al., 2005
3 Cheung et al., 2009
Cang Er Zi Xanthium sibiricum na Chau, 2008;
na Ma et al., 2014
Chang Shan Dichora febrifuga Lour na Ma et al., 2014
Chai Hu Bupleurum falcatum 28 Lee et al., 2011
Chaso Camellia sinensis, Cassia tora (syn. Senna), Crataegus, Chrysanthenum morifolium Ramat., Lotus, Lycium barbarum;
N-nitroso-fenfluramine
27 Adachi et al., 2003
Chi R Yun Breynia officinalis 2 Lin et al., 2002
19 Lin et al., 2003
Chinese herbal mixtures (various) Dictamnus dasycarpus, Gentiana scabra, Hedyotis diffusa, Paeonia suffructicosa, Paris
polyphylla, Rehmannia glutinosa, Smilax glabra, Sophora subprostrata;
1 Perharic-Walton and
Murray, 1992
Angelica sinensis, Bupleurum chinese, Dictamnus dasycarpus, Paeonia suffructiosa, Philodendron chinese, Saposhnikovia
divaricata, Shisandra chinesis, Shizonepeta tenuifolia, Tribulus terrestris;
2 Kane et al., 1995
Cocculus trilobus, Dictamnus dasycarpus, Eurysolen gracilis, Glycyrrhiza, Lophatherum, Paeonia, Potentilla, Rehmannia
glutinosa;
1 Vautier and Spiller,
1995
Alisma plantago aquatica, Artemisia capillaris, Bupleurum, Chrysanthemum morifolium, Circuma, Gardenia jasminoidis,
Gentiana scabra, Glycyrrhiza, Magnolia, Paeonia, Plantago asiatica, Saussurea lappa
1 Yoshida et al., 1996
Chuan Lian Zi Melia toosendan 1 Yuen et al., 2006
Ci Wu Jia Acanthopanax senticosus 2 Sohn et al., 2008
Da Chai Hu Tang Bupleurum falcatum, Ginseng, Glycyrrhiza glabra, Pinellia, Scutellaria, Zingiber officinale, Zizyphus jujuba 1 Kamiyama et al., 1997
Da Huang Rheum palmatum 1 Yuen et al., 2006
Du Huo Angelica archangelica 1 Björnsson et al., 2013
Fu Fang Qing Dai Wan Angelica dahurica, Isatis indigotica (Indigo naturalis), Massa medicata fermentata (yeast), Salvia
milthiorrhiza, Smilax glabra
1 Verucchi et al., 2002
Gan Cao Glycyrrhiza uralensis, syn. Liquorice 1 Yuen et al., 2006
Ge Gen Pueraria lobata, syn. Arrowroot 2 Kim et al., 2009
He Huan Pi Albizia julibrissin na Ma et al., 2014
Ho Shou Wu Polygonum multiflorum, syn. He Shou Wu 1 Yuen et al., 2006
(Continued)
Frontiers in Pharmacology | www.frontiersin.org 4 April 2015 | Volume 6 | Article 72
Teschke and Eickhoff Herbal hepatotoxicity
TABLE 1 | Continued
Name with ingredients Cases (n) References
na Ma et al., 2014
1 Bae et al., 2010
Hu Bohe You Mentha pulegium, syn. Pennyroyal oil na Chau, 2008
Hu Zhang Polygonum cuspidatum na Chau, 2008
Huang Qin Scutellaria baicalensis 19 Gono et al., 2010
2 Linnebur et al., 2010
1 Yang et al., 2012a;
1 Dhanasekaran et al.,
2013
Huang Yao Zi Dioscorea bulbifera na Chau, 2008;
na Ma et al., 2014
Hwang Geun Cho Corydalis speciosa 1 Kang et al., 2009
Ji Gu Cao Abrus cantoniensis 1 Yuen et al., 2006
Ji Ji Chloranthus serratus na Chau, 2008
Ji Xue Cao Centella asiatica, syn. Gotu Kola 3 Jorge and Jorge, 2005
Jiguja Hovenia dulcis 1 Sohn et al., 2008
1 Kang et al., 2008
1 Kim et al., 2012
Jin Bu Huan Lycopodium serratum or, rarely, Corydalis species, 7 Woolf et al., 1994
Panax ginseng, Pseudo ginseng, or two species of Stephania 3 Horowitz et al., 1996
1 Picciotti et al., 1998
1 Divinsky, 2002;
1 Haller et al., 2002
Jue Ming Zi Cassia obtusifolia, syn. Senna obtusifolia 1 Yuen et al., 2006
Kamishoyosan Angelica sinensis, Atractylodes racea, Bupleurum falcatum, Gardenia, Glycyrrhiza glabra, Mentha haplocalyx,
Moutan, Paeonia alba, Sclerotium Poriae Cocos, Zingiber officinale
1 Inoue et al., 2011
Kudzu Pueraria thunbergiana 6 Kang et al., 2008
Ku Lian Zi Melia azedarach na Ma et al., 2014
Lei Gong Teng Tripterygium wilfordii Hook na Chau, 2008
na Ma et al., 2014
Long Dan Xie Gan Tang Acebia, Alisma, Angelica sinensis, Bupleurum, Gardenia, Gentiana, Glycyrrhiza, Plantago,
Rehmannia, Scutellaria
17 Lee et al., 2011
Lu Cha Camellia sinensis, syn. Chinese green tea 1 Garcia-Moran et al.,
2004
1 Peyrin-Biroulet et al.,
2004
1 Gloro et al., 2005
1 Bonkovsky, 2006
1 Jimenez-Saenz and
Martinez-Sanchez,
2006
1 Bonkovsky, 2006
1 Molinari et al., 2006
5 Björnsson and Olsson,
2007
3 García-Cortés et al.,
2008
34 Sarma et al., 2008
36 Mazzanti et al., 2009
1 Rohde et al., 2011
47 Navarro et al., 2013
Ma Huang Ephedra sinica 1 Nadir et al., 1996
(Continued)
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TABLE 1 | Continued
Name with ingredients Cases (n) References
1 Borum, 2001
3 Estes et al., 2003
1 Skoulidis et al., 2005
1 Reuben et al., 2010
Mao Guo Tian Jie Cai Heliotropium lasiocarpum 4 Culvenor et al., 1986
Onshido Aloe, Camellia sinensis, Crataegus, Gynostemma pentaphyllum makino, Raphanus; N-nitroso-fenfluramine 141 Adachi et al., 2003
Qian Li Guang Senecio scandens na Chau, 2008;
na Ma et al., 2014
Ren Shen Panax ginseng 6 Kang et al., 2008
Sairei To Alisma, Atractylis, Bupleurum, Cinnamomum, Ginseng, Glycyrrhiza, 1 Aiba et al., 2007
Pinellia, Polyporus, Poria, Scutellaria, Zingiber, Zizyphus 1 Tsuda et al., 2010
Shang Lu Phytolacca acinosa na Ma et al., 2014
Shen Min Black cohosh, Burdock, Cayenne pepper, Ginkgo biloba, Horse chestnut, Piper nigrum, Polygonum multiflorum,
uva ursi; biotin, collagen (hydrolyzed), niacin, pantothenic acid, silica (from plant sources), soy isoflavones, vitamin A, vitamin B6
1 Cárdenas et al., 2006
Shi Can Teucrium chamaedrys, syn. Germander na Chau, 2008
Shi Liu Pi Pericarpium granati na Chau, 2008
Shou Wu Pian Achyranthes bidentata, Cuscuta chinensis, Eclipta prostrata, 1 But et al., 1996
Ligustrum lucidum, Lonicera japonica, Morus alba, Polygonum multiflorum, 1 Park et al., 2001
Psoralea corylifolia, Rehmannia glutinosa, Rosa laevigata, Sesemum indicum, 1 Battinelli et al., 2004
Siegesbeckia orientalis 1 Panis et al., 2005
3 Sohn et al., 2008
1 Laird et al., 2008
1 Furukawa et al., 2010
1 Valente et al., 2010
25 Jung et al., 2011
1 Banarova et al., 2012
Tian Hua Fen Trichosanthes kirilowii na Chau, 2008
Tu San Qi Gynura segetum 2 Dai et al., 2006
1 Chen et al., 2007
1 Li et al., 2010
52 Lin et al., 2011;
116 Gao et al., 2012
White flood Qian Ceng Ta (Huperzia serrata), Wu Zhu Yu (Evodia rutaecarpa); beet root, caffein, cocoa bean, vinpocetine
(from Vinca plant); acesulfame potassium, calcium silicate, carnitine tartrate, Carno-Syn® beta-alanine, citrulline,
cryptoxanthin, folic acid, gamma-aminobutyric acid (GABA), glucuronolactone, selenium, L-norvaline, L-tyrosine, lutein, malic
acid, ornithine, potassium gluconate, sucralose, sugar cane, watermelon flavor, zeaxanthin
1 Cohen et al., 2012
Wu Bei Zi Galla chinensis na Chau, 2008
Xi Shu Camptotheca acuminata na Chau, 2008
Xian Si Zi Abrus Precatorius na Ma et al., 2014
Xiao Chai Hu Tang Bupleurum falcatum, Ginseng, Glycyrrhiza glabra, 4 Itoh et al., 1995
Pinellia tuber, Scutellaria baicalensis, Zingiber officinale, Zizyphus jujuba 19 Lee et al., 2011
1 Hsu et al., 2006
Yin Chen Hao Artemisia capillaris 7 Kang et al., 2008
1 Sohn et al., 2008
Zexie Alisma orientalis 1 Yuen et al., 2006
Zhen Chu Cao Phyllanthus urinaria 1 Yuen et al., 2006
Data represent an update of cases retrieved from a selective literature search for published cases of herbal TCM associated with suspected hepatotoxicity (Teschke, 2014; Teschke
et al., 2014c, 2015b) and of a recent compilation most common Chinese herbal medicines with hepatotoxicity (Ma et al., 2014). In some cases, causality for individual herbs and herbal
mixtures was established using the CIOMS (Council for International Organizations of Medical Sciences) scale or its modifications, and by positive reexposure test results. For other
cases, information was fragmentary and did not necessarily allow a firm causal attribution.
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TABLE 2 | Compitalion of commonly used herbs and herbal products with
reported hepatotoxicity.
Search items Botanical names, ingredients, references
Acacia catechu see Ayurvedic herb
Asterceae family Adenostyles alliariae
(Sperl et al., 1995)
Aloe Aloe perfoliata var. vera
(Rabe et al., 2005; Kanat et al., 2006; Bottenberg
et al., 2007; Yang et al., 2010)
Amorphophallus
Konjac
see Hydroxycut®
Arrowroot Maranta aruninacea or Tacca leontopetaloides
(Kim et al., 2009)
Atractylis gummifera see Distaff thistle
Ayurvedic herbs Psoralea corylifolia, Acacia catechu, Eclipta alba or
Bacopa monnieri, Vetivexia zizaniodis
(Teschke and Bahre, 2009)
Babchi Psoralea corylifolia, see also Ayurvedic herbs
(Nam et al., 2005)
Bacopa monnieri see Ayurvedic herbs
Bajiaolian Dysosma pleianthum
(Kao et al., 1992)
Boronia Sm. see Pro-Lean®
Buchu Tea Agathosma betulina, Agathosma crenulata
(Engels at al., 2013)
Bush tea Crotalaria species
(Smith and Culvenor, 1981)
Callile pis laureola see Impila
Camellia sinensis see green tea, Exolise®, and Hydroxycut®
see X-elles®
Cascara sagrada Rhamnus purshianus
(Nadir et al., 2000)
Cassia angustifolia see Senna
Centella asiatica see Gotu Kola, see Pro-Lean®
Chamaerops humilis see Saw Palmetto
Chaparral Larrea tridentata, Larrea divariatica
syn. Creosot (Katz and Saibil, 1990; Centers of Disease Control
and Prevention, 1992; Smith and Desmond, 1993;
Alderman et al., 1994; Batchelor et al., 1995;
Gordon et al., 1995; Sheikh et al., 1997; Haller
et al., 2002; Estes et al., 2003)
Chelidonium majus see Greater Celandine, see Lycopodium
similiaplex®
Chinese herbs Unknown or up to 12 ingredients
Chlorophora species see Kambala tea
Chrysanthemum
leucanthemum
see Oxeye Daisy
Citrus aurantium see X-elles®
Citrus paradisum see X-elles®
Cyrana scolymus see X-elles®
Cola nitida see Pro-Lean®
Coltsfoot Tussilago farfara
(Roulet et al., 1988)
Comfrey Symphytum officinale, Symphytum asperum,
Symphytum uplandicum
(Ridker et al., 1985; Weston et al., 1987; Bach
et al., 1989; Ridker and McDermott, 1989; Miskelly
and Goodyer, 1992)
(Continued)
TABLE 2 | Continued
Search items Botanical names, ingredients, references
Compositae species see Indian herbs
Creosot see Chaparral
Crotalaria species see Bush tea, see Rattlebox
Cyperus see Pro-Lean®
Distaff thistle Atractylis gummifera
(Georgia, 1988)
Eclipta alba see Ayurvedic herbs
Emblica officinalis see Isabgol
Ephedra species Ephedra californica, Ephedra sinica
(Estes et al., 2003)
Exolise® Garcinia cambogia, Gymnema sylvestre, White
kidney bean, Camellia sinensis, L-Carnitine
fumarate, Calcium, Magnesium chelate, Chromium
chelate, Conjugated linoleic acid, Chitosan
(McDonnell et al., 2009)
Fallopia multiflora see Pro-Lean®
Foeniculum amare see Herbalife®
Fucus vesiculosus see Pro-Lean®
Garcinia cambogia see Exilis®, see Herbalife®, see Hydroxycut®
Germander Teucrium chamaedrys, Teucrium polium
(Larrey et al., 1992; Mostefa-Kara et al., 1992; Dao
et al., 1993; Mattéi et al., 1995; Laliberté and
Villeneuve, 1996; Starakis et al., 2006)
Ginkgo biloba see Pro-Lean®
Ginseng see Bai Fang, see Dai Saiko To, see Pro-Lean®,
see Xiao Chai Hu Tan
Glycyrrhiza glabra see Dai Saiko To, see Xiao Chai Hu Tang
Gotu Kola Centella asiatica
(Jorge and Jorge, 2005)
Greater Celandine Chelidonium majus, see also Lycopodium
similiaplex®
(Strahl et al., 1998; Greving et al., 1998; Benninger
et al., 1999; Crijns et al., 2002; Hardeman et al.,
2003; Stickel et al., 2003; BfArM, 2005; Rifai et al.,
2006; Conti et al., 2008; Moro et al., 2009;
Tarantino et al., 2009; EMA, 2010; Teschke et al.,
2011a, 2012a, 2013b)
Green tea Camellia sinensis, see also Lu Cha (Table 1)
(Duenas Sadornil et al., 2004; Garcia-Moran et al.,
2004; Abu el Wafa et al., 2005; Gloro et al., 2005;
Bonkovsky, 2006; Javaid and Bonkovsky, 2006;
Jimenez-Saenz and Martinez-Sanchez, 2006;
Molinari et al., 2006; Martinez-Sierra et al., 2006;
Björnsson and Olsson, 2007; Federico et al., 2007;
Liss and Lewis, 2009; Sarma et al., 2008; Mazzanti
et al., 2009; Verheist et al., 2009; Rohde et al.,
2011; Teschke et al., 2011e, 2014e; Teschke and
Schulze, 2012)
Groundsel Senecio longilobus, Senecio species
syn. Senecio Stillman et al., 1977; Fox et al., 1978
Guaraná Paullinia cupana
(Dara et al., 2008)
Gymnema sylvestre see Exilis®, see Hydroxycut®
Hawthorn see Crataegus
Hedeoma pulegoides see Pennyroyal
Heliotropium Heliotropium eichwaldii, Heliotropium species
(Continued)
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(Mohabbat et al., 1976; Datta et al., 1978; Tandon
et al., 2008; Kakar et al., 2010)
Herbalife® Solidaginis gigantea, Ilex paraguariensis,
Petroselinum crispum, Garcinia cambogia, Spiraea,
Matricaria chamomilla, Liquiritia, Foeniculum amare,
Humulus lupulus, Chromium, and various other
ingredients
(Hoffmann et al., 2005; Duque et al., 2007; Elinav
et al., 2007; Schoepfer et al., 2007; Chao et al.,
2008; Manso et al., 2008; Stickel et al., 2009; Chen
et al., 2010; Jóhannsson et al., 2010; Appelhans
et al., 2011; Manso et al., 2011; Appelhans et al.,
2012; Manso, 2012; Halegoua-De Marzio et al.,
2013; Teschke et al., 2013b)
Horse chestnut see Venencapsan®, see Venoplant®
Hydroxycut® Camellia sinensis, Gymnema sylvestre,
Amorphophallus Konjac, Paullinia cupana, Garcinia
cambogia, Caffeine, α-Lipoic acid, L-Carnitine,
Calcium, Potassium, Chromium
(Stevens et al., 2005; Jones and Andrews, 2007;
Dara et al., 2008; Shim and Saab, 2009; Chen
et al., 2010; Fong et al., 2010)
Humulus lupulus see Herbalife®
Ilex paraguariensis see Herbalife®, see Maté
Impila Callilepis laureola
(Wainwright et al., 1977; Wainwright and
Schonland, 1977; Popat et al., 2001)
Indian herbs Compositae species
(Kumana et al., 1983)
Iroko see Kambala tea
Isabgol Plantago ovata, Emblica officinalis
(Fraquelli et al., 2000)
Kambala tea Chlorophora excelsa, Chlorophora regia
syn. Iroko (Gunawan and Kaplowitz, 2004)
Kava Piper methysticum
(Strahl et al., 1998; Escher et al., 2001; BfArM,
2002; Bujanda et al., 2002; Denham et al., 2002;
Weise et al., 2002; Estes et al., 2003; Gow et al.,
2003; Humberston et al., 2003; Russmann et al.,
2003; Schulze et al., 2003; Teschke et al., 2003,
2008a,b, 2011b, 2012c; Schmidt et al., 2005;
WHO, 2007a; Christl et al., 2009; Teschke and
Wolff, 2009, 2011; Teschke, 2010a,c; Teschke and
Schulze, 2010; Teschke and Lebot, 2011; Schmidt,
2014)
Larrea divariatica see Chaparral
Larrea tridentata see Chaparral
Leucanthemum vulgare see Oxeye Daisy
Liquiritia see Herbalife®
Lycopodium serratum
foot clubmass
see Lycopodium similiaplex®, see Wolf’s
Lycopodium
similiaplex®
Lycopodium serratum, Chelidonium majus
(Conti et al., 2008)
Maranta aruninacea see Arrowroot
Maté Ilex paraguariensis
(McGee et al., 1976)
Matricaria chamomilla see Herbalife®
Mentha pulegium see Pennyroyal
(Continued)
TABLE 2 | Continued
Search items Botanical names, ingredients, references
Mistletoe Viscum album
(Harvey and Colin-Jones, 1981; Hyde, 1981;
Colin-Jones and Harvey, 1982; Farnsworth and
Loub, 1982; Stirpe, 1983)
Monascus purpureus see Red Yeast Rice
Morinda citrifolium see Noni
Nerium oleander see Oleander
Noni Morinda citrifolium
(Millonig et al., 2005; Stadlbauer et al., 2005, 2008;
Yüce et al., 2006; López-Cepero Andrada et al.,
2007; Yu et al., 2011; Mrzljak et al., 2013)
Oleander Nerium oleander
(Altan et al., 2009)
Oxeye Daisy Leucanthemum vulgare, Chrysanthemum
leucanthemum
(Mokhobo, 1976)
Paullinia cupana see Guaraná, see Hydroxycut®, see Pro-Lean®
Pennyroyal Mentha pulegium, Hedeoma pulegoides
(Vallance, 1955; Sullivan et al., 1979; Anderson
et al., 1996; Bakerink et al., 1996)
Petroselinum crispum see Herbalife®
Petroselinum sativum see X-elles®
Piper methysticum see Kava
Phaseolus vulgaris see Exilis ®
Plantago ovata see Isabgol
Pro-Lean® Ma Huang, Paullinia cupana, Cola nitida, Centella
asiatica, Salix alba,Ginkgo biloba, Fucus
vesiculosus, Boronia Sm., Ginseng, Fallopia
multiflora, Cyperus, Bee pollen, Caffeine, L-Tyrosine,
Chromium, Vanadium, Magnesiumsalicylat,
Folsäure, Vitamin B12,and various other ingredients
(Joshi et al., 2007)
Psoralea corylifolia see Ayurvedic herbs
Pyrrolizidine alkaloids see Bush tea, see Comfrey, see Groundsel, see
Heliotropium species,
see Indian herbs, see Maté, see Rattlebox
Rattlebox Crotalaria species
syn. Crotalaria (Tandon et al., 1976a,b)
Red Yeast Rice Monascus purpureus
(Roselle et al., 2008)
Rhamnus purshianus see Cascara sagrada
Rooibos Tea Aspalathus linearis
(Engels et al., 2013)
Salix alba see Pro-Lean®
Sassafras Sassafras albidum
(Larrey, 1997; Zimmerman, 1999)
Saw Palmetto Serenoa serpens, Chamaerops humilis
(Lapi et al., 2010)
Scullcap Scutellaria lateriflora, Scutellaria species
(MacGregor et al., 1989; Caldwell et al., 1994; Hullar
et al., 1999; Estes et al., 2003; Yang et al., 2012a)
Scutellaria species see Scullcap
Senecio see Groundsel
Senna Cassia angustifolia
(Beuers et al., 1991; Seybold et al., 2004;
Vanderperren et al., 2005)
(Continued)
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Serenoa serpens see Saw Palmetto
Solidaginis gigantea see Herbalife®
Spiraea see Herbalife®
Symphytum see Comfrey
Tacca leontopetaloides see Arrowroot
Teucrium see Germander
Tussilago farfara see Coltsfoot
Valerian Valeriana officinalis
(MacGregor et al., 1989; Mennecier et al., 1999)
Valeriana officinalis see Valerian
Venencapsan® Aesculus hippocastanum, Chelidonium majus,
Melilotus officinalis, Milfoil, Silybum Adans.,
Taraxacum officinale
(De Smet et al., 1996)
Venoplant® Aesculus hippocastanum
(Takegoshi et al., 1986)
Vetivexia zizaniodis see Ayurvedic herbs
Viscum album see Mistletoe
Wolf’s foot clubmass Lycopodium serratum
(Woolf et al., 1994; Horowitz et al., 1996; Conti
et al., 2008)
X-elles® Petroselinum sativum, Citrus aurantium, Citrus
paradisum, Cyrana scolymus, Camellia sinensis
(Mathieu et al., 2005)
Data are retrieved from a selective literature search for selective reports of herbs and
herbal products with hepatotoxicity and actualized from a previous report (Teschke et al.,
2012h). In numerous cases, causality was proposed, but not necessarily established and
open for discussion.
Latency period describes the interval between initiation of herb
use and time of onset, evidenced by emerging symptoms or
increased liver values. Liver injury by herbal TCM develops
slowly with clinical symptoms appearing between 1 week and 1
month (Ma et al., 2014), or up to 150 days (Chau et al., 2011);
with a longer latency period of 5–260 weeks for green tea extracts
(GTE) (Mazzanti et al., 2009; Teschke et al., 2014a); or 1 week–24
months for other herbs such as kava (Teschke et al., 2008a); and
28–134 days for Greater Celandine (GC) (Teschke et al., 2011a).
Finally, published HILI symptoms (Chau et al., 2011; Teschke
et al., 2013a;Ma et al., 2014) are similar to those of DILI (Andrade
et al., 2004; Liss and Lewis, 2009).
Clinical Course
The clinical course of HILI is variable with details provided in
most publications as referenced (Tables 1, 2). For HILI cases,
some details of treatment modalities by herbal products of tra-
ditional and modern medicine are provided, with focus on daily
and cumulative dose, treatment duration, latency period, and
reexposure duration (Table 5). With cessation of herbal use, clin-
ical signs usually vanish along with improvements or normaliza-
tion of initially increased liver values, as illustrated by few exam-
ples (Verucchi et al., 2002; Vanderperren et al., 2005; Teschke
and Bahre, 2009; Furukawa et al., 2010; Valente et al., 2010; Yang
et al., 2010). A well described dechallenge of liver values in sus-
pected HILI is one of the key items to suspect causality for a
particular herb. Patients with HILI caused by herbal TCM or
modern herbal medicine commonly experience an acute type of
liver injury, which is self-limited upon withdrawal of the offend-
ing herb with an overall good prognosis. Whether herbs may
cause chronic forms of HILI has not yet been evaluated in detail
(García-Cortés et al., 2008). However, persistence of increased
liver values raises the question whether these are due to a pre-
existing liver disease present prior to herbal use rather than to
HILI (Picciotti et al., 1998). The acute type of HILI rarely may
progress to acute liver failure (Stadlbauer et al., 2005; Fong et al.,
2010). This is a serious condition that may require a liver trans-
plant and eventually leads to death (Perharic-Walton and Mur-
ray, 1992; Yoshida et al., 1996; Haller et al., 2002; Adachi et al.,
2003; Estes et al., 2003; Yuen et al., 2006; Sohn et al., 2008; Fong
et al., 2010). Between 1992 and 2008; in Seoul (Korea) alone, 24
patients underwent liver transplantation due to toxic hepatitis
caused by herbal TCM (Sohn et al., 2008), causing concern in
view of poorly documented efficacy of herbal TCM (Manheimer
et al., 2009; Teschke, 2014).
Cessation of herbal use is the only therapeutic approach for
HILI patients. Other options including evidence based therapy
for treating patients with HILI are lacking, but on a case basis
treatment was reported with glycyrrhizin (Inoue et al., 2011),
ursodesoxycholic acid (Jorge and Jorge, 2005; Inoue et al., 2011),
or corticosteroids (Weinstein et al, 2012).
Hepatotoxicity Criteria
HILI case assessment mandates clear hepatotoxicity criteria for
disease characterization including causality assignment (Teschke
et al., 2013f, 2014b). Laboratory-based criteria of HILI are best
defined by alanine aminotransferase (ALT) and/or alkaline phos-
phatise (ALP) values, expressed as N in multiples of the upper
limit of their normal range (Figure 1). For ALT, recommenda-
tions initially were at >2N (Bénichou et al., 1993; Danan and
Bénichou, 1993) and currently are at>5N (Björnsson et al., 2012;
Teschke et al., 2014c,d) or at 3N if total bilirubin values exceed 2N
(Aithal et al., 2011); for ALP, values of >2N are considered diag-
nostic (Bénichou et al., 1993; Danan and Bénichou, 1993; Aithal
et al., 2011). Restricting the ALT criteria to >5N will eliminate
unspecific ALT increases and substantiate causality at a high level
of probability (Björnsson et al., 2012). Considering patients with
ALT values of>2Nwill initially also include numerous cases with
nonspecific increases, which then require thorough assessment
and stringent exclusion of causes unrelated to the used herb(s).
For low threshold values, the rate of alternative diagnoses is high
(Teschke et al., 2013g), findings that are plausible and not unex-
pected (Teschke et al., 2014e). Other values such as aspartate
aminotransferase (AST) are not required, unless to be used as
substitute for ALT if not available.
Concern emerges whenever hepatotoxicity is assumed even
if liver values were only marginally increased, not reported,
or not assessed. These problems are not uncommon for cases
of assumed HILI, presented for instance by the US Pharma-
copeia (USP) (Mahady et al., 2008) relating to both black
cohosh (BC) (Teschke, 2010c; Teschke et al., 2011d,e; Teschke
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TABLE 3 | Compilation of narrative case details and clinical data of patients with HILI by Greater Celandine (GC) and established causality.
Patient Identification Specific information for each individual patient
01 (Strahl et al., 1998),
42 years Female
GC extract of known brand name and manufacturer (3 capsules/day containing each 200mg of probably dried herb for 9 months).
Bloating as indication for treatment. Latency period of 2 months for first symptoms of itching and jaundice, at rechallenge 1 month.
ALT 755U/L, AST 350U/L, ALP 221U/L. Upon cessation of GC treatment, rapid decrease but not normalization of ALT values
reported. Readministration of GC with positive result. Exclusion of virus hepatitis A-C and infections of other hepatotropic viruses
reported, with lack of any details regarding hepatitis A, B, and C, CMV, EBV, HSV, or VZV. Exclusion of biliary obstruction by
sonography. Exclusion of autoimmune hepatitis reported with lack of specified parameters. Normal values of iron and copper
parameters. Liver histology: Acute hepatitis with confluent liver cell necroses and little inflammation.
Final diagnosis: highly probable GC hepatotoxicity.
02 (Benninger et al.,
1999), their case five
37 years Female
GC extract as drug of known brand name and manufacturer (unknown dose/day for 3 months). Atopic eczema as indication for GC
treatment. Various herbal and homeopathic drugs as CD. Latency period of 3 months until symptoms of nausea and jaundice. ALT
813U/L, AST 898U/L, ALP 249U/L. ALT course described. Positive reexposure test for GC. Five months after GC discontinuation,
normalization of liver parameters reported. Exclusion of infections by HAV, HBV, HBC, HEV, CMV, and EBV. SMA 1:40, exclusion of
AIH. Ultrasound examination with normal bile ducts. Liver histology not done.
Final diagnosis: highly probable GC hepatotoxicity.
03 (Benninger et al.,
1999), their case six
65 years Female
GC extract of unknown brand name and manufacturer (unknown dose/day for 3 months). Dyspepsia as indication for GC treatment.
Latency period and symptoms not recorded. No CD. ALT 152U/L, AST 89U/L, ALP 451U/L. After GC discontinuation, ALT course
not sufficiently documented. Normalization of liver values 3 months after GC withdrawal. Exclusion of common causes for hepatitis
reported, but lack of information regarding specific parameters. Lack of ultrasound data. Liver histology: Moderate drug induced
hepatitis with low grade single cell necrosis.
Final diagnosis: probable GC hepatotoxicity.
04 (Crijns et al., 2002),
42 years Female
Herbal mixture of GC and curcuma root (Curcuma longa rhizoma) of known brand name and manufacturer (unknown dose/day for 2
months). Not further described skin complaints as indication for treatment. Before admission, paracetamol (500mg) tablet on one
day. Latency period: 5 weeks until jaundice. Fever 40.5◦C for 2 weeks, starting 2 weeks after initiation of GC treatment. ALT
1490U/L, AST 838U/L, ALP 265U/L. Following cessation of the herbal mixture, ALT course described with normalization of liver
values after 2 months. Exclusion of acute hepatitis A-C and infections by CMV, and EBV, but HSV and VZV not assessed. Normal
titres of ANA, but no data of AMA, SMA, and LKM. Sonography with normal biliary tract. Liver histology: Severe acute hepatitis of
viral or toxic drug cause.
Final diagnoses: probable GC hepatotoxicity and possible curcuma hepatotoxicity.
05 (Stickel et al., 2003),
their case two
69 years Male
GC extract as drug of known brand name and manufacturer (80 capsules within 5–6 weeks). Postprandial abdominal discomfort as
indication for GC treatment. Latency period of 5–6 weeks until symptoms of weakness, abdominal pain in the right upper quadrant,
nausea, jaundice, and dark brown urine. Medical history included cholecystectomy 4 years ago. Lack of regular comedication. Alcohol
consumption below 20g/day. ALT 881U/L, AST 466U/L, ALP 312U/L. ALT course not recorded. Exclusion of acute viral hepatitis
including HAV, HBV, HCV, CMV, EBV. Autoimmune parameters not assessed. By abdominal ultrasound and magnetic resonance
tomography common and intrahepatic bile ducts inapparent. Liver histology: Cholestatic hepatitis compatible with drug toxicity.
Final diagnosis: probable GC hepatotoxicity.
06 (Rifai et al., 2006),
58 years Male
GC extract as drug of known brand name and manufacturer (unknown amounts of tablets/day for 3 weeks). Biliary spasms as
indication for GC treatment. Latency period: of 3 weeks until fatigue, dark urine, itching, jaundice, and pale stool. No CD. ALT
903U/L, AST 380U/L, ALP 516U/L. After GC withdrawal well documented ALT course with ALT normalization within 4 weeks. Well
documented exclusion of hepatitis A–C, and E, and of infections by CMV, EBV, HSV, and VZV reported. Well documented exclusion
of infectious, autoimmune, metabolic, and genetic causes of acute hepatitis. Sonography with slightly thickening of the gall bladder
and otherwise normal biliary tract. Liver histology: Lobular hepatitis with severe cholestasis and moderate inflammation that included
also the bile ducts.
Final diagnosis: probable GC hepatotoxicity, but also possible causality for biliary disease.
07 (Conti et al., 2008),
46 years Female
GC extract as solution of known brand name and manufacturer, containing also other herbs as are Lycopodium serrata, Carduus
marianus, Hamamelis, Ruta, Sepia, Pulsatilla, Collinsonia, and Hydrastis (50 drops/day for 8 weeks). Insomnia and for sedation as
indication for treatment. Latency period of 8 weeks until symptoms of nausea, anorexia, asthenia, and abdominal discomfort. Herbal
mixture with various herbs and the potentially hepatotoxic Lycopodium serrata as CD. ALT 2,364U/L, AST 737U/L, ALP 255U/L.
Rapid decrease of ALT in the further course following treatment cessation with normalization after 2 months. Exclusion of HAV, HBV,
HCV, CMV, EBV, and HSV. Specified serological tests for autoimmune diseases negative. Sonography without reported biliary tract
abnormalities. Liver histology: Moderate mixed inflammatory infiltrate with eosinophils.
Final diagnoses: probable GC hepatotoxicity, probable Lycopodium serratum hepatotoxicity.
08 (Moro et al., 2009),
65 years Male
GC extract as herbal tea derived from GC leaves (1 cup/day for 1 month). Pyrosis as indication for GC treatment. Lansoprazole
15mg/day for 2 years as current CD. Latency period of 1 month. Asthenia, dyspepsia, dark urine, and jaundice as symptoms. ALT
4765U/L, AST 3235U/L, ALP not reported. ALT course not reported, but normalization of all liver parameters within 2 months. Three
months before symptom onset, treatment with clarithromycin and amoxicillin for 1 week. All antibodies for not further
(Continued)
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specified hepatic viruses resulted negative except for anti-HCV that was found positive despite negative HCV-PCR. Autoimmune
parameters not reported. Hepatomegaly by ultrasound examination. Liver histology: Moderate drug induced hepatitis.
Final diagnosis: probable GC hepatotoxicity.
09 BfArM, 2005,
95003848
32 years Male
GC extract as drug of known brand name and manufacturer (2 capsules/day for not clearly defined duration). Upper abdominal pains
as indication for treatment. Latency period not report ed, jaundice as symptom. ALT 2196U/L, AST 714U/L, ALP 256U/L. Upon
cessation of GC treatment, decrease but not normalization of ALT and AST values, with lack of reported ALP value. Readministration
of GC with pruritus and not further specified increases of liver values and lack of complete resolution upon dechallenge. Overall
course of ALT not sufficiently documented, neither at first and second dechallenge, nor in the interval and after the second challenge.
Undulating ALT values of unknown clinical significance. Exclusion of virus hepatitis reported, with lack of any details regarding hepatitis
A, B, and C, CMV, EBV, HSV, or VZV. Exclusion of biliary obstruction by sonography and ERCP. Exclusion of autoimmune hepatitis
with lack of reported parameters. Normal values of ceruloplasmin, α-1 Antitrypsin, and electrophoresis. Liver histology: Unspecific
hepatitis with liver cell necroses. Poorly documented case including questionable rechallenge and lack of ALT normalization.
Final diagnosis: probable GC hepatotoxicity.
10 BfArM, 2005,
96026841
55 years Female
GC extract as drug of known brand name and manufacturer (3 capsules/day for 6 weeks). Upper abdominal pains as indication for
treatment. Latency period of 6 weeks with jaundice as symptom. Diltiazem 90 for several years and doxycycline for 10 days (start
prior to jaundice) for treatment of erythema migrans as CD. ALT 2,016U/L, AST 620U/L, ALP 398U/L. After cessation of GC
treatment, normalization of ALT not reported and with 201U/L on day 19 still increased. Overall ALT course poorly documented.
Exclusion of hepatitis A, B, and C reported without details of assessed parameters. Lack of exclusion of virus infections by CMV, EBV,
HSV, and VZV. Negative results for AMA, SMA, LKM, and actin. Exclusion of biliary obstruction by sonography and ERCP. Liver
histology: compatible with drug induced liver injury
Final diagnosis: highly probable GC hepatotoxicity.
11 BfArM, 2005,
98000501
65 years Male
GC extract as drug of known brand name and manufacturer (2–3 capsules/day for 42 days). To increase bile flow after
cholecystectomy 20 years ago as indication for treatment. Latency period of 42 days with itching and jaundice as symptoms. ALT
461U/L, AST 355U/L, ALP 260U/L, normalization not reported. After GC discontinuation, on day 12 ALT 235U/L. Exclusion of
hepatitis A–C and of infections by CMV, EBV, HSV, and VZV. AMA negative, exclusion of autoimmune hepatitis reported but individual
parameters not described. Upon sonography and ERCP normal bile ducts after cholecystectomy.
Final diagnosis: highly probable GC hepatotoxicity.
12 BfArM, 2005,
98001447
49 years Female
GC extract as drug of known brand name and manufacturer (3 tablets/day for 4 weeks). Upper abdominal pains as indication for
treatment. Latency period of 3.5 weeks with reduced appetite, bloating, epigastric pain, nausea, vomiting, and jaundice as symptoms.
ALT 2928U/L, AST 1116U/L, ALP 408U/L. After GC discontinuation, on day 7 ALT was 1356U/L, and on day 20 it was 426U/L.
Normalization of ALT has not been reported. Exclusion of hepatitis A-C, E and F, and of infections by CMV, EBV, and HSV, but not of
VZV. Normal values of ANA, AMA, and SMA. Upon ultrasound and ERC, normal bile ducts and cholecystolithiasis or cholesterol
polyps of the gallbladder, by ultrasound questionable cholecystitis. Liver histology: Severe portal hepatitis with beginning fibrosis.
Final diagnosis: probable GC hepatotoxicity.
13 BfArM, 2005,
98001607
59 years Female
GC extract as drug of known brand name and manufacturer (3 tablets/day for 7 weeks). Vomiting, upper abdominal pains and
gastro-esophageal reflux as indications for treatment. Latency period 20 days with tiredness, exhaustion, nausea, vomiting, and
jaundice as symptoms. Asthma, treated with various sprays, and latent hyperthyroidism without treatment as comorbidities. Maximum
values reported for ALT 960U/L, AST 421U/L, and ALP 425U/L, with decrease but not normalization following GC discontinuation,
but actual results have not been reported. Through histology, ERCP, and serology (HAV, HBV, HCV) other hepatobiliary diseases
excluded, but details not reported. Missing exclusion of infections by CMV, EBV, HSV, and VZV. Poorly documented case.
Final diagnosis: probable GC hepatotoxicity.
14 BfArM, 2005,
98008527
60 years Female
GC extract as drug of known name and manufacturer (3 capsules/day for several weeks). General discomfort as indication for
treatment. Latency period of several weeks with abdominal pains, nausea, and jaundice as symptoms. Crataegus extract as CD. ALT
420U/L, AST 451U/L, ALP 288U/L. At discharge after 4 weeks, ALT with 26U/L still slightly elevated. Exclusion of acute hepatitis
A–C and infections by CMV, and EBV, but HSV and VZV not assessed. Normal titres of ANA, AMA, SMA, and LKM. Sonography and
ERCP with normal biliary tract. Liver histology: AIH or dug induced liver injury.
Final diagnosis: probable GC hepatotoxicity.
15 (BfArM, 2005),
00000278
65 years Male
GC extract as drug of known brand name and manufacturer (3 capsules/day for 4 weeks). Bloating as indication for treatment.
Latency period of 3.5 weeks with jaundice as symptom. Diclofenac (intermittent), sitosterols, butizide, raubasine, rescinnamine, and
reserpine as CD. ALT 950U/L, AST 570U/L, normal ALP. Under treatment with cortisone and at discharge, ALT 193U/L, but
normalization of ALT with and without cortisone not reported. Exclusion of hepatitis A–C and of infections by CMV, EBV, and HSV
reported. Normal titres of ANA, AMA, and SMA. Sonography and ERCP with normal biliary tract. Liver histology: Hepatitis with
cholestasis.
Final diagnosis: probable GC hepatotoxicity.
(Continued)
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16 (BfArM, 2005),
02001171
66 years Female
GC extract as drug of known brand name and manufacturer (0–2 capsules/day for 4.5 months). Dyspepsia as indication for
treatment. Latency period of 4.5 months with reduced appetite and jaundice as symptoms. ALT 760U/L, AST 408U/L, ALP 337U/L.
On day 14 after GC cessation, ALT 379U/L, and on day 24 ALT 207U/L. Normalization of ALT not reported. Exclusion of hepatitis
A–C reported, but details not presented. No exclusion of infections by CMV, EBV, HSV, and VZV. Autoimmune parameters not done.
Sonography, MRCP and MRT with normal biliary tract. Insufficiency of the mitral valve.
Final diagnosis: probable GC hepatotoxicity.
Narrative compilation with details of relevant clinical data of 16 patients with liver injury by the use of the herb Greater Celandine (GC), data are derived from a review article (Teschke
et al., 2012a) and based on previous reports (Teschke et al., 2011a, 2012e). In these studies, highly probable and probable causality levels for GC were established in all patients
presented as final diagnoses, using the updated CIOMS scale for the individual causality assessment. Half of the patients (cases 01–08) were derived from published case reports, the
other half (cases 09–16) from spontaneous reports of the German regulatory agency (BfArM, 2005). Outcome was favorable in all cases. Abbreviations: AIH, autoimmune hepatitis;
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies; AST, aspartate aminotransferase; BfArM, Bundesinstitut für
Arzneimittel und Medizinprodukte, Bonn; CD, comedicated drug(s); CIOMS, Council for International Organizations of Medical Sciences; CMV, cytomegalovirus; EBV, Epstein Barr virus;
ERCP, endoscopic retrograde cholangiopancreaticography; GC, Greater Celandine; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; HSV, herpes simplex virus; LKM,
liver kidney microsomal antibodies; MRCP, magnetic resonance cholangiopancreaticography; MRT, magnetic resonance tomography; PCR, polymerase chain reaction; SMA, smooth
muscle antibodies; VZV, varicella zoster virus.
TABLE 4 | Preferred documentation as example: clinical characteristics of GC hepatotoxicity.
Characteristics of HILI by GC
Characterization of GC hepatotoxicity as a specific disease entity was feasible and based on high causality levels for GC in 16 patients with liver disease.
Causality for GC was graded highly probable and probable in 4 and 12 patients, respectively.
Among these 16 patients, there was an additional causality for comedicated curcuma graded as possible, for comedicated Lycopodium serratum graded as probable,
and for biliary disease graded as possible.
The existence of GC hepatotoxicity has been verified by a positive reexposure test in two patients
Ages of the 16 patients ranged from 32 to 69 years with an average of 54.7 years, and the ratio of females: males was 10: 6.
Comedication with synthetic or herbal drugs and dietary supplements including herbal ones and herbal mixtures was used in the majority of assessable cases.
On average, the patients used 10mg chelidonine daily with lack of daily overdose in any of the cases.
Treatment duration was 3 weeks to 9 months with an average of 2.4 months.
Latency period until first symptoms was 3 weeks to 4.5 months with an average of 1.7 months, which was considerably shorter than the treatment length.
Jaundice was the most frequently reported symptom, rarely also weakness, anorexia, nausea, vomiting, abdominal pains, dark urine, pale stools, and itching.
High serum activities are found for ALT but not for ALP, suggestive of a hepatocellular type of toxic liver injury in patients with GC hepatotoxicity.
Histology showed predominantly liver cell necrosis and hepatitis.
Outcome was favorable in all 16 patients, with lack of both acute liver failure and requirement of a liver transplant.
In one patient, good prognosis was sustained even after 7 months of continued GC Use despite presence of emerging GC hepatotoxicity.
GC hepatotoxicity usually represents the hepatocellular and idiosyncratic type of liver injury with its metabolic subgroup, characterized as acute clinical course.
The underlying mechanism(s) leading to GC hepatotoxicity as well as possible culprit(s) are still unknown.
In cases of liver disease, causality for GC was verified and creates concern regarding safety of patients and pharmacovigilance considerations.
Due to lack of epidemiologic data, the incidence of GC hepatotoxicity cannot accurately be calculated but appears to be low.
Preferred documentation: The data are based on the cases of 16 patients with GC hepatotoxicity and highly probable or probable causality levels for GC and derived from a previous
report (Teschke et al., 2012a). Abbreviations: ALT, alanine aminotransferase; ALP, alkaline phosphatase; GC, Greater Celandine.
and Schulze, 2012) and green tea extracts (Sarma et al., 2008;
Liss and Lewis, 2009); by the WHO, relating to kava (WHO,
2007a; Teschke and Wolff, 2009); the German regulatory agency
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
(BfArM, 2002, 2005) relating to kava (Schmidt et al., 2005;
Teschke et al., 2008a); or the Drug Commission of the Ger-
man Medical Association (DCGMA, 2011) relating to Pelargo-
nium sidoides (PS) (Teschke et al., 2012b,e). In published case
reports receiving the benefit of appropriate peer reviews, the
presented HILI cases commonly provide high values of amino-
transferases and/or ALP and basic data support of potential
hepatotoxicity, as shown also for some cases with a positive
reexposure test results (Teschke et al., 2014b). In other HILI
case series, however, criteria were not or incompletely docu-
mented; neglecting these aspects in effect invalidates the causality
assessment.
In spontaneous reports of regulatory agencies, a clear hep-
atotoxicity definition was provided by EMA (2007) but not by
the U.S. Pharmacopeia (USP) (Mahady et al., 2008; Sarma et al.,
2008), the German BfArM (2002), or the WHO (2007a). For
instance, EMAmentions cases with assumedHILI by BC but clar-
ifies that a causal attribution cannot be made with the required
certainty in face of missing liver values (EMA, 2007). Conse-
quently, missing regulatory hepatotoxicity definitions represent
Frontiers in Pharmacology | www.frontiersin.org 12 April 2015 | Volume 6 | Article 72
Teschke and Eickhoff Herbal hepatotoxicity
TABLE 5 | Some chracteristics of daily and cumulative doses, treatment duration, latency period, and reexposure period of cases with hepatotoxicity by
herbs of traditional and modern medicine.
Case Sex Herb Herbal mixture Daily dose Cumulative Treatment Latency Reexposure References
Age dose duration period duration
1. F/62y Aloe 420mg 37800mg 3.0 month 2.75 month 1.0 month Yang et al., 2010
2. M/71y Chaparral 1 tablet 90 tablets 3.0 month 3.5 month 1.0 month Batchelor et al., 1995
3. F/39y Chinese herbal mixture n.a. n.a. 2.0 month 2.0 month 0.1 month Kane et al., 1995
4. F/ 9y Chinese herbal mixture n.a. n.a. 6.0 month 5.25 month 1.0 month Davies et al., 1990
5. F/66y Chinese Jin Bu Huan 0–2 tablets 60 tablets 3.0 month 2.75 month 0.5 month Woolf et al., 1994
6. M/46y Chinese Jin Bu Huan 0–3 tablets 216 tablets 6.0 month 6.0 month 1.0 month Woolf et al., 1994
7. F/52y Chinese Syo Saiko To 7.5 g 338 g 1.5 month 1.5 month 1.0 month Itoh et al., 1995
8. F/58y Chinese Syo Saiko To 7.5 g 675 g 3.0 month 3.0 month 0.25 month Itoh et al., 1995
9. F/42y Chinese Syo Saiko To 7.5 g 158 g 0.75 month 0.75 month 0.07 month Itoh et al., 1995
10. F/54y Germander 600mg 23,400mg 1.3 month 1.3 month 1.0 month Larrey et al., 1992
11. F/25y Germander n.a. n.a. 4.0 month 4.0month 0.75 month Larrey et al., 1992
12. M/48y Germander 900mg 81,000mg 3.0 month 3.75 month 0.33 month Larrey et al., 1992
13. F/45y Germander 260mg 468,00mg 6.0 month 6.0 month 0.25 month Laliberté and Villeneuve, 1996
14. F/42y Greater Celandine 600mg 162,000mg 9.0 month 2.0 month 1.5 month Strahl et al., 1998
15. F/56y Green tea 14ml 210ml 4.0 month 3.3 month 1.0 month Jimenez-Saenz and
Martinez-Sanchez, 2006
16. F/37y Green tea n.a. n.a. 4.0 month 4.0 month 1.0 month Bonkovsky, 2006
17. F/63y Herbalife n.a. n.a. 4.0 month 3.5 month n.a. Hoffmann et al., 2005
18. F/39y Kava 60mg 10,800mg 6.0 month 6.0.month 0.5 month Strahl et al., 1998
19. F/49y Mistletoe 50mg 1500mg 1.0 month 1.0 month 1.0 month(?) Harvey and Colin-Jones, 1981
20. M/61y Polygonum multiflorum n.a. n.a. 0.033 month 0.033 month 0.033 month Jung et al., 2011
21. F/26y Senna 100mg 12,000mg 4.0 month 3.0 month n.a. Beuers et al., 1991
In all 22 hepatotoxicity cases, causality for the respective herb or herbal mixture was ascertained by positive reexposure test results based on established criteria. Unclear: ?, Adapted
data from a previous report (Teschke et al., 2014b).
confounding variables and result in false high signal cases due to
regulatory case overreporting and overdiagnosing (Teschke et al.,
2013f).
For reasons of transparency and assessment of case data qual-
ity, each HILI case series should provide tabulated information
of available or missing case details, as done in various reports
(Teschke et al., 2011a, 2012b,e) and shown as example (Table 6)
(Teschke, 2010c).
HILI Case Characteristics
Hepatotoxicity classification is mandatory in cases of assumed
HILI to facilitate further evaluation of reexposure results and
CIOMS assessments (Teschke et al., 2013f). Based on specific
laboratory constellations, differentiation of the hepatocellular,
cholestatic or mixed form of hepatotoxicity is feasible by compar-
ing serum activities of ALT and ALP at the time HILI diagnosis is
first suspected (Bénichou et al., 1993; Danan and Bénichou, 1993;
Teschke et al., 2014d). Enzyme activity is expressed as a multiple
of the upper limit of the normal range (N), and the ratio (R) of
ALT/ALP is calculated. Liver injury is classified as hepatocellular,
if ALT> 2N alone or R = 5; cholestatic, when there is an increase
of ALP > 2N alone or when R = 2; of the mixed type if ALT >
2N, ALP is increased, and 2 < R < 5 (Figure 1). In a HILI case
series of herbal TCM consisting of 27 patients, the pattern of liver
injury was hepatocellular in 82% of the cases, cholestatic in 11%,
and mixed in 7% (Chau et al., 2011).
Liver Histology
Liver biopsy in HILI and DILI cases requires special attention in
any clinical hepatology setting, balancing benefits and risks for
the patient (Teschke and Frenzel, 2014). Published and sponta-
neous HILI reports often contain detailed histological descrip-
tions of liver biopsy findings, mostly associated with pictures
obtained by microscopy. This erroneously implies that liver
biopsy is an essential part of routine case assessments (BfArM,
2002; Teschke et al., 2008a, 2011a, 2012a,b,f,g; Teschke, 2010c).
Histology data were also presented by narrative HILI case reports
lacking even any causality for a particular herb (Teschke et al.,
2012f,g). This raises the question whether a liver biopsy is jus-
tified, considering also that there were no histological findings
recognized as specific for all hepatotoxicity cases (Ramachandran
and Kakar, 2009). Liver biopsy in chronic hepatotoxicity cases to
define prognosis in the absence of an expected specific therapy
option remains debatable (Teschke and Frenzel, 2014).
To evaluate liver histology findings, a retrospective case anal-
ysis of pathological changes in HILI selectively caused by one
single herb with established causality appears the best approach.
For instance, HILI cases of kava and GC have such an estab-
lished causality track. In 12 GC HILI patients with a probable or
highly probable causality grading for GC, prevailing histological
features included hepatitis, single or confluent liver cell necro-
sis, inflammation, rarely fibrosis, and cholestasis (Teschke et al.,
2011a, 2012a,e). In eight HILI patients with a highly probable,
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FIGURE 1 | Strategy for assessing HILI cases according to details
presented previously (Teschke et al., 2013f). Abbreviations: ALP, alkaline
phosphatase; ALT.
probable or possible causality for kava, liver histology showed
hepatitis, liver cell necrosis, and rarely bile duct proliferation and
intrahepatic cholestasis (Teschke et al., 2008a). Therefore, at least
for the two herbs GC and kava, the histological features are quite
uniform and restricted to two major features, hepatitis and liver
cell necroses. These histological characteristics, however, are also
found in most other liver diseases unrelated to herbs, obviating
liver biopsy in suspected HILI cases due to unspecific results.
Additional insights are provided by the analysis of cases with
positive reexposure tests, done unintentionally with the incrimi-
nated herb or herbal mixture, and available liver histology results.
For instance, in HILI by a herbal mixture of TCM, total liver
necrosis prevailed (Perharic-Walton andMurray, 1992); german-
der (Teucrium chamaedrys) caused hepatocyte necrosis with lob-
ular inflammatory infiltrationmainly by mononuclear cells, asso-
ciated with slightly fibrous portal tracts containing inflammatory
cells (Larrey et al., 1992); senna use resulted in liver cell necrosis
around the central veins as well as portal and lobular infiltra-
tion by lymphocytes, histiocytes, and rare plasma cells (Beuers
et al., 1991); chaparral intake was associated with hepatocellu-
lar necrosis combined with inflammation, portal tract expansion,
mild cholestasis and fibrous septation (Batchelor et al., 1995);
and the herbal TCM Chinese skullcap (Scutellaria baicalensis)
was considered to cause acidophil bodies, ballooned hepatocytes,
lobular inflammatory cell infiltrates including eosinophils, and
portal tracts containing mononuclear cells and eosinophils (Yang
et al., 2012a). Based on causality established by positive reex-
posure results, these few examples may provide some insight in
morphological liver changes due to herbal use.
Histological features usually are not clinically relevant, but
some clinicians still consider a liver biopsy an important part
of the diagnostic work-up in suspected hepatotoxicity cases. The
question is whether histological results changed the initial diag-
nosis or benefited the individual patient. In two cases of ini-
tially suspected HILI, however, histological findings of giant cell
hepatitis were reported and completely ignored (Dunbar and
Solga, 2007; Schoepfer et al., 2007), while the clinical course
and this particular histological pattern best fitted with an exist-
ing severe virus infection with hepatic involvement rather than
herbal hepatotoxicity (Teschke and Schwarzenboeck, 2009).
Clearly, the pathologist is not helpful offering diagnoses such
as HILI or liver injury compatible with or suggestive for herbal
use. Overall, liver histology as a supporting routine method for
assessing HILI cases is not recommended, it commonly adds little
new specific diagnostic clues as information to the case with-
out benefit for the patient; as an invasive procedure, rare but
potentially life threatening complications may occur (Teschke
and Frenzel, 2014).
Alternative Causes
Unrecognized alternative diseases are a real clinical problem
when caring for patients with initially assumed but later not con-
firmed HILI. Several hundred liver diseases have to be considered
as diagnoses alternative to HILI, to be ruled out under clini-
cal aspects and with specific diagnostic tools. As a reminder for
clinicians, a checklist with details for these alternative diagnoses
is available (Table 7) (Teschke et al., 2014d). Numerous missed
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TABLE 6 | Preferred documentation as example: overview of known information regarding all 69 patients with primarily suspected but not established
HILI by black cohosh (BC).
Presented information Cases Individual cases
Brand name 22/69 1,5,11,12,13,14,15,16,17,18,19,20,21,22,23,24,28,29,30,31,32,33
Manufacturer 12/69 1,5,11,17,18,20,28,29,30,31,32,33
Plant part 06/69 1,5,8,11,28,33
Solvent 02/69 1,11
Daily dose 11/69 1,3,5,6,7,11,12,13,16,17,18
BC drug 07/69 1,11,19,21,23,24,31
BC herbal supplement 01/69 5
BC polyherbal product 14/69 2,3,12,13,14,15,16,17,18,20,22,28,30,33
Date of BC start 20/69 1,3,4,5,6,7,8,10,11,12,13,15,18,20,21,22,27,28,29,33
Date of BC end 17/69 1,3,4,5,6,7,8,10,11,12,13,15,18,19,20,21,22
Date of symptoms 24/69 1,2,3,4,5,6,7,8,10,11,12,13,14,15,16,18,19,20,21,22,23,27,32,33
Temporal association 12/69 1,4,5,6,8,10,12,13,18,20,21,22
Time on BC 16/69 1,3,4,5,6,7,8,10,11,12,13,15,18,20,21,22
Time to onset 19/69 1,3,4,5,6,7,8,9,10,11,12,13,18,20,21,22,27,28,33
ALT value 15/69 1,2,3,4,5,6,7,8,10,11,12,13,15,23,32
ALP value 12/69 1,2,3,4,5,6,7,11,12,13,23,32
Hepatotoxicity criteria 14/69 1,2,3,4,5,6,7,8,10,11,12,13,23,32
ALT de-challenge 06/69 4,6,7,10,11,15
Biliary tract imaging 08/69 4,5,6,7,9,10,15,28
HAV 13/69 1,2,3,4,5,6,7,8,9,10,11,14,15
HBV 12/69 1,3,4,5,6,7,8,9,10,11,14,15
HCV 13/69 1,2,3,4,5,6,7,8,9,10,11,14,15
CMV 09/69 1,4,5,6,8,10,11,14,15
EBV 09/69 1,4,5,6,8,10,11,14,15
HSV 03/69 4,6,8
VZV 01/69 8
Co-medication/herbal mixture 23/69 2,3,4,5,6,7,11,12,13,14,15,16,17,18,20,22,23,27,28,29,30,32,33
BC undetermined product 13/69 4,6,7,8,9,10,25,26,27,29,32,34–69
PreferreThe group of the 69 cases consisted of 11 case reports (cases 1–11), 13 TGA cases from Australia (cases 12–24), 2 CADRMP cases from Canada (cases 25 and 26), 7
MedWatch/ FDA cases from the United States (cases 27–33), and 33 EMA cases from the European Union (cases 34–69). Details and references of the 69 cases were published earlier
(Teschke et al., 2010). Abbreviations: ALP, alkaline phosphatase; ALT alanine aminotransferase; BC, black cohosh; CMV, cytomegalovirus; EBV, Epstein Barr virus; HAV, hepatitis A virus,
HBV, hepatitis B virus, HCV, hepatitis C virus; HSV, herpes simplex virus; VZV, varicella zoster virus.
diagnoses were found upon reevaluation of initially assumed
HILI cases, with similar problems for DILI (Figure 2) (Teschke
et al., 2013g, 2014a). Exclusion of hepatitis E and infections by
cytomegalovirus (CMV), Epstein Barr virus (EBV), herpes sim-
plex virus (HSV), and varicella zoster virus (VZV) should be
obligatory rather than facultative (Table 7).
Causality Evaluation
Reexposure
Establishing the diagnosis of HILI may be cumbersome in the
usual clinical setting, with experts not available in place and in
time. Since, convincing biomarkers for all HILI cases are lacking,
the gold standard for the diagnosis of hepatotoxicity still is a pos-
itive unintentional reexposure test result, if available (Bénichou
et al., 1993; Danan and Bénichou, 1993; García-Cortés et al., 2008;
Chalasani and Björnsson, 2010). Details of essential criteria are
based on the conclusions of an International Consensus Meet-
ing, as referred previously (Bénichou et al., 1993). Accordingly,
required data are baseline ALT levels before reexposure, designed
ALTb, and reexposure ALT levels, designed ALTr. The reexpo-
sure test is positive, if ALTr= 2ALTb and ALTb is below 5N, with
N as the upper limit of the normal value (Table 8). Other vari-
ations lead to uninterpretable results. Some HILI reports men-
tioned a positive reaction upon reexposure, and these cases were
further analyzed. Not all reexposure tests could be confirmed,
partially due to lack of any details; however, for numerous herbs
and herbal preparations of TCM and modern medicine, valid
reexposure test results confirmed causality in the assessed HILI
cases (Table 9) (Teschke et al., 2014b,d); using these cases, some
characteristic features of daily and cumulative doses, divergences
between treatment duration and latency period, and reexposure
duration are evident (Table 5).
CIOMS/RUCAM
Physicians at armlength from the patient with HILI are well
advised to consider a pragmatic thorough clinical evaluation
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TABLE 7 | Differential diagnoses of HILI.
Differential diagnosis Diagnostic parameters Diagnostic exclusion done
for patient’s assessment
Yes NO Partial
Hepatitis A Anti-HAV-IgM 2 2 2
Hepatitis B Anti-HBc-IgM, HBV-DNA 2 2 2
Hepatitis C Anti-HCV-IgM, HCV-RNA 2 2 2
Hepatitis E Anti-HEV-IgM, Anti-HEV-IgG, HEV-RNA 2 2 2
Cytomegalovirus (CMV) CMV-PCR, titre change for Anti-CMV-IgM and Anti-CMV-IgG 2 2 2
Epstein Barr virus (EBV) EBV-PCR, titre change for Anti-EBV-IgM and Anti-EBV-IgG 2 2 2
Herpes simplex virus (HSV) HSV-PCR, titre change for Anti-HSV-IgM and Anti-HSV- IgG 2 2 2
Varicella zoster virus (VZV) VZV-PCR, titre change for Anti-VZV-IgM and Anti-VZV- IgG 2 2 2
Other virus infections Specific serology of Adenovirus, Coxsackie-B-Virus, Echovirus, Measles virus,
Rubella virus, Flavivirus, Arenavirus, Filovirus, Parvovirus, HIV, and others
2 2 2
Other infectious diseases Specific assessment of bacteria, fungi, parasites, worms, and others 2 2 2
Autoimmune hepatitis (AIH) type I Gamma globulins, ANA, SMA, AAA, SLA/LP, Anti-LSP, Anti-ASGPR 2 2 2
Autoimmune hepatitis (AIH) type II Gamma globulins, Anti-LKM-1 (CYP 2D6), Anti-LKM-2 (CYP 2C9), Anti-LKM-3 2 2 2
Primary biliary cholangitis (PBC) AMA, Anti PDH-E2 2 2 2
Primary sclerosing cholangitis (PSC) p-ANCA, MRC 2 2 2
Autoimmune cholangitis (AIC) ANA, SMA 2 2 2
Overlap syndromes See AIH, PBC, PSC, and AIC 2 2 2
Non alcoholic steatohepatitis (NASH) BMI, insulin resistance, hepatomegaly, echogenicity of the liver 2 2 2
Alcoholic liver disease (ALD) Patient’s history, clinical and laboratory assessment, sonography 2 2 2
Drug induced liver injury (DILI) Patient’s history, clinical and laboratory assessment, sonography, use of the
CIOMS scale
2 2 2
Cocaine, ecstasy and other amphetamines Toxin screening 2 2 2
Rare intoxications Toxin screening for household and occupational toxins 2 2 2
Hereditary hemochromatosis Serum ferritin, total iron-binding capacity, genotyping for C2824 and H63D
mutation, hepatic iron content
2 2 2
Wilson’s disease Copper excretion (24 h urine), ceruloplasmin in serum, free copper in serum,
Coombs-negative hemolytic anemia, hepatic copper content,
Kayser-Fleischer-Ring, neurologic-psychiatric work-up, genotyping
2 2 2
Porphyria Porphobilinogen in urine, total porphyrines in urine 2 2 2
α1—Antitrypsin deficiency α1—Antitrypsin in serum 2 2 2
Biliary diseases Clinical and laboratory assessment, hepatobiliary sonography, MRC 2 2 2
Pancreatic diseases Clinical and laboratory assessment, sonography, CT, MRT 2 2 2
Celiac disease TTG antibodies, endomysium antibodies, duodenal biopsy 2 2 2
Anorexia nervosa Clinical context 2 2 2
Parenteral nutrition Clinical context 2 2 2
Cardiopulmonary diseases Cardiopulmonary assessment of congestive heart disease, myocardial infarction,
cardiomyopathy, cardiac valvular dysfunction, pulmonary embolism, pericardial
diseases, arrhythmia, hemorrhagic shock, and various other conditions
2 2 2
Addison’s disease Plasma cortisol 2 2 2
Thyroid diseases TSH basal, T4, T3 2 2 2
Grand mal seizures Clinical context of epileptic seizure (duration > 30min) 2 2 2
Heat stroke Shock, hyperthermia 2 2 2
Polytrauma Shock, liver injury 2 2 2
Systemic diseases Specific assessment of M. Boeck, amyloidosis, lymphoma, other malignant
tumors, sepsis, and others
2 2 2
Other diseases Clinical context 2 2 2
This tabular compilation represents an update of a previous version (Teschke et al., 2013f). AAA, Anti-actin antibodies; AMA, antimitochondrial antibodies; ANA, antinuclear antibodies;
ASGPR, Asialo-glycoprotein-receptor; BMI, body mass index; CIOMS, Council for International Organizations of Medical Sciences; CT, computer tomography; CYP, cytochrome P450;
DPH, pyruvate dehydrogenase; HAV, hepatitis A virus; HBc, Hepatitis B core; HBV, hepatitis B virus; HCV, hepatitis C virus; HEV, hepatitis E virus; HILI, herb induced liver injury; HIV,
human immunodeficiency virus; LKM, liver kidney microsomes; LP, liver-pancreas antigen; LSP, liver specific protein; MRC, magnetic resonance cholangiography; MRT, magnetic res-
onance tomography; p-ANCA, perinuclear antineutrophil cytoplasmatic antibodies; PCR, polymerase chain reaction; SLA, soluble liver antigen; SMA, smooth muscle antibodies; TSH,
thyroid stimulating hormone; TTG, tissue transglutaminase.
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FIGURE 2 | Missed diagnoses in cases of initially suspected
hepatotoxicity by herbs and synthetic drugs. Adapted from a previous
report (Teschke et al., 2013f), which provides the respective references for
each item presented above. Abbreviations: CMV, cytomegalovirus; EBV,
Epstein Barr virus; HSV herpes simplex virus; LKM, liver kidney microsomes;
SMA, smooth muscle antibodies; VZV, varicella zoster virus.
in connection with a prospective structured approach assessing
causality, providing the diagnosis in time while the disease is
unfolding and without delay due to waiting periods for expert
rounds’ conclusions months thereafter; this is a crucial issue
worldwide.We clearly prefer the CIOMS scale (Council for Inter-
national Organizations of Medical Sciences), also called RUCAM
(Roussel Uclaf Causality Assessment Method), in its original
form (Bénichou et al., 1993; Danan and Bénichou, 1993) or better
its update (Tables 10, 11) (Teschke et al., 2013a, 2014d). Discus-
sions focused on strengths and weaknesses of CIOMS, a learn-
ing system and not immutable (Andrade et al., 2004; Rochon
et al., 2008; Aithal et al., 2011; García-Cortés et al., 2011; Teschke
and Wolff, 2011; Teschke and Schulze, 2012; Teschke et al.,
2008c, 2013e, 2014d; Lewis, 2014; NIH, 2014b). Outlined sug-
gestions for improvement and refinement are incorporated in
the updated CIOMS scale (Tables 10, 11) (Teschke et al., 2013e,
2014d). Included is now the search for additional competing
causes such as sepsis; or autoimmune hepatitis, chronic hepatitis
B and C, primary biliary cholangitis and sclerosing cholangitis,
and genetic liver diseases. HBsAg and HBV-DNA quantification
were added to distinguish HBV infection from immunization,
as was HCV-RNA to correctly assess HCV infections. Specific
diagnostic criteria now include PCR detection and titer changes
of the respective antibodies (IgM, IgG) for CMV, EBV, HEV,
HSV, and VZV infections. Hepatobiliary sonography was sup-
plemented by color Doppler sonography including assessments
of the liver vessels, endosonography, computed tomography
(CT), and magnetic resonance cholangiography (MRC. Alco-
hol as risk factor is now specified by an intake of >2 drinks
per day (>14 units/week) in woman and >3 drinks per day
(21 units/week) in men, whereby one drink corresponds to 10 g
ethanol. For comparison and method validation, causality has
been evaluated in 101 hepatotoxicity cases by both the original
and updated CIOMS scales, with identical causality results pub-
lished in 6 studies (Teschke et al., 2014d).Therefore, the updated
CIOMS scale was validated, and there is no need for further
validation of the updated CIOMS scale vs. the original CIOMS
scale.
A selective compilation shows that numerous international
registries and regulatory agencies as well as associated groups
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TABLE 8 | Conditions of unintentional reexposure tests in suspected HILI
cases.
Reexposure Hepatocellular type Cholestatic (±hepatocellular)
test result of liver injury type of liver injury
ALTb ALTr ALPb ALPr
Positive <5N ≥2ALTb <2N ≥2ALPb
Negative <5N <2ALTb <2N <2ALPb
Negative ≥5N ≥2ALTb ≥2N ≥2ALPb
Negative ≥5N <2ALTb ≥2N <2ALPb
Uninterpretable <5N n.a. <2N n.a.
Uninterpretable n.a. ≥2ALTb n.a. ≥2ALPb
Uninterpretable n.a. n.a. n.a. n.a.
Conditions and criteria for an unintentional reexposure test, adapted from a previous
report (Teschke et al., 2014b). Accordingly, required data for the hepatocellular type of liver
injury are the ALT level, just before reexposure, designed as baseline ALT or ALTb, and
the ALT levels during reexposure, designed as ALTr. Response to reexposure is positive, if
both criteria are met: first, ALTb is below 5N with N as the upper limit of the normal value,
and second ALTr ≥2ALTb. Other variations lead to negative or uninterpretable results.
For the cholestatic (±hepatocellular) type of liver injury, corresponding values of ALP are
to be used rather than of ALT. Abbreviations: ALP, Alkaline phosphatase; ALT, Alanine
aminotransferase; n.a., not available.
actually apply CIOMS for HILI and DILI cases (Table 12),
with its advantages over other causality assessing approaches
(Teschke et al., 2013a) including the method of DILIN (Drug-
Induced Liver Injury Network) (Table 13). As opposed to the
DILIN method, CIOMS fascinates by its stringent scoring sys-
tem (Table 13), with its generation of a quantitative assessment
(score) to address probability, which is more precise than a
simple yes or no (Gunawan and Kaplowitz, 2004). Support for
CIOMS was actually provided by Navarro as DILIN member
and senior author of a HDS case series by applying CIOMS for
causality assessment (Halegoua-De Marzio et al., 2013), whereas
CIOMS was not in favor of Lewis, another DILIN member
(Lewis, 2014). Although, connected with an actual commentary
on a single HILI case report that did not undergo any formal
causality assessment, Navarro also correctly acknowledged that
CIOMS/RUCAM is the most frequently referenced scoring sys-
tem (Fenkel and Navarro, 2011). This assumption supports ear-
lier systematic analyses of 2008 (Tajiri and Shimizu, 2008). Of 61
DILI reports that were reviewed in the PubMed database over
the last decade, showing that CIOMS was the most used scale.
In a recent confirmative study of 573 HILI cases (Table 14),
CIOMS again was the most used method applied in 275 cases
(48.0%) (Teschke et al., 2013g), in line with mainstream opin-
ion (Tables 12, 14) (Wai, 2006; Aithal et al., 2011; NIH, 2014a,b;
Björnsson et al., 2012, 2013. The CIOMS scale was widely used
for hepatotoxicity assessments in epidemiological studies, clinical
trials, case reports, case series, regulatory analyses, and geno-
typing studies, as referenced in detail recently (Teschke et al.,
2013f).
CIOMS is structured, quantitative, and specific and validated
for hepatotoxicity, and considers all its core elements (Tables 10,
11) (Teschke et al., 2014d). It was developed by an international
expert panel and validated by cases with positive reexposure
tests as gold standard, showing good sensitivity (86%), specificity
(89%), positive predictive value (93%), and negative predictive
value (78%) (Bénichou et al., 1993). Of note, the scales for the
hepatocellular and the cholestatic (± hepatocellular) type of
injury differ slightly (Tables 10, 11).
The CIOMS scale was conceptualized and developed in con-
sensus meetings organized at the request of the Council for Inter-
national Organizations of Medial Sciences (CIOMS) (Bénichou
et al., 1993; Danan and Bénichou, 1993), aiming to overcome
experts’ previous problems with unstructured and unquantified
evaluations lacking defined and scored items,resulting in debated
causality assignments. This CIOMS scale represented a break-
through in DILI and HILI causality assessment methods and
extended, specified, and quantified preceding versions (Danan,
1988; Bénichou, 1990). The basis for CIOMS was provided by
eight experts in hepatology from 6 countries and included J. P.
Benhamou (France), J. Bircher (Germany), G. Danan (France),
W. C. Maddrey (USA), J. Neuberger (UK), F. Orlandi (Italy), N.
Tygstrup (Denmark), and H. J. Zimmerman (USA) (Bénichou
et al., 1993; Danan and Bénichou, 1993). These experts in the field
evaluated DILI cases for case characteristics, hepatotoxicity crite-
ria, liver injury pattern, and reexposure criteria; they standard-
ized DILI case assessment with specific, quantitative items and
validated their method with established positive reexposure DILI
case results (Bénichou et al., 1993; Danan and Bénichou, 1993).
CIOMS was developed for assessment of a single drug containing
a synthetic product and may be used for a single herb contain-
ing multiple chemical constituents, but does not allow causality
attribution to a single constituent.
CIOMS provides a differentiating range of causality grades for
the responsible agent(s) and clearly delineates liver specific crite-
ria for challenge, dechallenge, exclusion of unrelated diseases, and
comedication (Bénichou et al., 1993; Danan and Bénichou, 1993).
It even takes into account atypical chronology with +1 point for
challenge periods of <5 days or > 90 days, whereas the period
of 5–90 days renders +2 points (Table 10). It is well adapted for
cases with missing data. Physicians suspecting herbal hepatotox-
icity can easily use CIOMS, results are readily available within a
few minutes.
To facilitate valid actual assessment and possible external
reevaluation, CIOMS scale data should be provided individ-
ually point by point for each patient (Tables 10, 11), along
with the list of alternative diagnoses to be excluded (Table 7).
In publications of HILI cases and for submission to regula-
tory agencies as spontaneous reports, the completed CIOMS
scale with all items including individual and final scores
should be supplied to ensure data transparency, as published
before (Teschke et al., 2008a, 2011a,d,e, 2012b,d,h; Teschke
and Bahre, 2009; Teschke, 2010a,c) and presented as exam-
ple, using the CIOMS scale of the hepatocellular type of injury
(Table 15).
Thus, we strongly recommend for HILI case assessment a
sequential approach, starting with thorough clinical evaluations
and concomitant prospective causality evaluation by the updated
CIOMS scale (Tables 10, 11), followed by optional expert opin-
ion based on scored CIOMS items, if uncertainty remains, and
finally for reasons of transparency, appropriate documentation
of case details (Tables 3, 6, 7, 15).
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TABLE 9 | Analysis of reported positive reexposure test results in cases of suspected herbal Traditional Chinese Medicine (TCM) induced liver injury.
Case reexposure tests in cases of suspected herbal TCM induced liver injury
Chinese herbal mixtures
• 28-year old UK woman (Perharic-Walton and Murray, 1992): Chinese herbal mixture with 8 different herbs for 3–5 months. Jaundice. ALT value not available.
Reexposure: episode of hepatitis reported without liver values, acute liver failure, died despite emergency liver transplantation. Both ALTb and ALTr not available→
uninterpretable reexposure.
• 39-year old UK woman (Kane et al., 1995): Chinese herbal mixture with eight different herbs for 2 months. Short history of anorexia, nausea, fatigue, dark urine, yellow
sclerae, jaundice. ALT 2440U/L (normal 0–30) with R 68.3, ALT returned to normal after cessation. Reexposure after 6 weeks: ALT 1314U/L. ALTb < 5N and ALTr = 2
ALTb→ positive reexposure.
• 9-year old UK girl (Allen and Parkinson, 1990): Unclassified Chinese herbal medicine for 6 months. Nausea, anorexia, central abdominal pain, jaundice, pale stool for the
past 4–21 days. ALT 1950U/L (normal < 45) with R 13.1, ALT returned to 50U/L after cessation. Intentional reexposure: ALT 315U/L. ALTb < 5N and ALTr = 2ALTb→
positive reexposure.
Ho Shou Wu
• 54-year old Korean woman (Bae et al., 2010): Unknown dose of Ho Shou Wu containing Polygonum multiflorum for one month. Diagnosis of toxic hepatitis. Cessation
of Ho Shou Wu improved her condition. Reexposure started immediately after discharge with aggravation of liver values. English abstract and Korean article→
uninterpretable reexposure.
Huan Qin
• 78-year old US woman (Yang et al., 2012a): Move Free Advanced® two tablets/day containing Huan Qin (Scutellaria baicalensis, Chinese skullcap), black catechu,
glucosamine, and chondroitin for 3 weeks. Jaundice. ALT 1626U/L (normal < 60) with R 10.2, ALT 678U/L two weeks after cessation. Reexposure: ALT 1206U/L. ALTb
= 5N and ALTr < 2ALTb→ negative reexposure.
Hwang Geun Cho
• 37-year old male patient from Korea (Kang et al., 2009): Hwang Geun Cho containing Corydalis speciosa. Jaundice. ALT 531U/L with subsequent decline after
cessation of the herb down to 146 U/ L. Unintentional reexposure two months after discharge: ALT 381U/L. ALTb < 5N and ALTr = 2ALTb→ positive reexposure.
Ji Xue Cao
• 61-year old Argentinian woman (Jorge and Jorge, 2005): Ji Xue Cao (Centella asiatica, syn.Gotu Kola) tablets for 30 days. Jaundice. ALT 1193U/L and 2 months after
cessation 18U/L. Unintentional reexposure 7 months later: ALT 481U/L. ALTb < 5N and ALTr = 2ALTb→ positive reexposure.
• 52-year old female patient from Argentinia (Jorge and Jorge, 2005): Ji Xue Coa (Centella asiatica) for 6 months. Jaundice. Not further quantified elevated hepatic
enzymes at beginning and after cessation. Unintentional reexposure 1 year later: ALT 1694U/L. ALTb not availabe→ uninterpretable reexposure.
Jin Bu Huan
• 66-year old US woman (Woolf et al., 1994): Jin Bu Huan 2 tablets at night two to three times a week for twelve weeks. Fever, nausea, fatigue for the past 5 weeks. ALT
782U/L (normal < 35) with R 8.7, ALT declined to 47U/L following cessation. Reexposure: ALT 941U/L. ALTb < 5N and ALTr = 2 ALTb→ positive reexposure.
• 46-year old US man (Woolf et al., 1994): Jin Bu Huan three tablets three times a week intermittently for 6 months. Fever, headaches, fatigue, tender hepatomegaly. ALT
394U/L (normal < 35) 2 weeks after cessation with R 24.2, ALT subsequently 48U/L. Reexposure: ALT 100U/L. ALTb < 5 N and ALTr = 2 ALTb→ positive reexposure.
• 50-year old US woman (Horowitz et al., 1996): Jin Bu Huan two to three tablets daily or intermittently for around 24 days. Fever. ALT 830U/L and 330U/L after
cessation. Reexposure: ALT 540U/L. ALTb = 5N and ALTr < 2ALTb→ negative reexposure.
• 70-year old US woman (Horowitz et al., 1996): Jin Bu Huan three to four tablets at night three to five times a week for 31 days. Chills and fever 12 days after start of
use, subsequently low-grade fever, malaise. ALT 408U/L initially, 263U/L after 2- week cessation, 67U/L after 6-week cessation. Reexposure after 1 month: ALT 77U/L.
ALTb < 5N but ALTr < 2ALTb→ negative reexposure.
Lu Cha
• 56-year old French woman (Peyrin-Biroulet et al., 2004): Mincifit® 14ml/day containing green tea (Camellia sinensis, TCM Lu Cha) and Cassia sp. extracts for 15 days.
Jaundice. ALT 54N with R 54.0, ALT normalization 2 months after cessation. Reexposure 5 years later with Dynasvelte forte® 8–12 g/day for 21 days (Green tea, Coffea
Arabica, and chromium): ALT 99N. ALTb < 5N and ALTr = 2ALTb→ positive reexposure.
• 45-year old Spanish man (Jimenez-Saenz and Martinez-Sanchez, 2006): Green tea infusion (6 cups/day) over 4 months. Asthenia and jaundice of ten days duration
prior to cessation. ALT 1613U/L (normal < 40) with R 4.3, ALT normalized within 2 months of cessation. Reexposure 6 weeks later: ALT 1460U/L after 1 month of reuse.
ALTb < 5N and ALTr = 2ALTb→ positive reexposure.
• 37-year old Hispanic woman from the US (Bonkovsky, 2006): Green tea-containing product with various other herbal extracts for 4 months. Jaundice. ALT 1788U/L
(normal < 40) with R 21.7, ALT 92U/L after withdrawal. Reexposure 1 year later for 1 month: ALT 1131U/L. ALTb < 5N and ALTr = 2ALTb→ positive reexposure.
• 23-year old Spanish woman García-Cortés et al., 2008: Green tea (Camellia sinensis) for 21 days. Jaundice after 19 days. ALT 56.9N with R 34.7, ALT 0.35N 3 months
after withdrawal. Reexposure: ALT values not available. ALTb < 5N but ALTr not available→ uninterpretable reexposure.
• 26-year old Spanish woman García-Cortés et al., 2008: Green tea for 121 days. Jaundice. ALT 32.1N with R 42.2, ALT dechallenge values not available. Reexposure:
ALT values not available. Both ALTb and ALTr not available ? uninterpretable reexposure.
• 38-year old French woman (Sarma et al., 2008): Green tea (six caps Tealine®/day, containing also white and red tea) for 20 days. Symptoms not reported. ALT values
not available. Reexposure: ALT value not available. Both ALTb and ALTr not available→ uninterpretable reexposure.
(Continued)
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TABLE 9 | Continued
Ma Huang
• 33-year old US woman (Nadir et al., 1996): Unknown daily dose of Ma Huang for around 4 weeks. Nausea, vomiting, abdominal discomfort after use for several days,
jaundice under continuing Ma Huang use for another three weeks. ALT 832U/L (normal < 65) with R 9.8. ALT dechallenge values not available. Intentional reexposure
with a single dose 1 week after discharge: ALT 1586U/L. Both ALTb and ALTr not available ? uninterpretable reexposure.
Polygonum multiflorum
• 61-year old Korean man (Jung et al., 2011): Unknown dose of Polygonum multiflorum Thunb for 1 day. Myalgia. ALT 818U/L with R 21.6, 180U/L after 9 days of
cessation and ALTb < 5N as likely assumed. Reexposure after 11.5 months with a single dose of P. multiflorum Thunb: ALT 1520U/L. ALTb < 5N and ALTr = 2ALTb→
positive reexposure.
Shou Wu Pian
• 5-year old Netherland girl (Panis et al., 2005): Shou Wu Pian (three tablets daily) for four months. Jaundice. ALT 1543U/L (normal < 39U/L), 5 weeks after cessation
50U/L. Reexposure with tablets Shou Wu Pian daily for 1 month: ALT 1277U/L. ALTb < 5N and ALTr = 2ALTb→ positive reexposure.
Xiao Chai Hu Tang
• 51-year old Japanese woman (Itoh et al., 1995): 7.5 g of Xia Chai Hu Tang daily for 7 weeks. Jaundice, with preexisting mild elevations of aminotransferases. ALT
855U/L (normal < 35) with R 35.9, ALT decrease to 139U/L upon cessation. Reexposure: ALT 186U/L. ALTb < 5N but ALTr < 2 ALTb→ uninterpretable reexposure.
• 52-year old Japanese woman (Itoh et al., 1995): Xia Chai Hu Tang 7.5 g daily for 6 weeks. Jaundice, preexistent ALT activity of 180U/L (normal < 35). ALT 600U/L,
near normal 2.5 months after withdrawal. Reexposure: ALT 162U/L. ALTb < 5N and ALTr = 2ALTb→ positive reexposure.
• 58-year old Japanese woman (Itoh et al., 1995): Xia Chai Hu Tang 7.5 g daily for 3 months. Symptoms not reported. ALT 246U/L (normal < 35) with R 5.0, ALT fell to
near normal after 2 months of withdrawal. Intentional 7-day reexposure: ALT 265U/L. ALTb < 5N and ALTr = 2ALT→ positive reexposure.
• 42-year old Japanese woman (Itoh et al., 1995): Xia Chai Hu Tang 7.5 g daily for an unspecified time period to treat hepatitis A infection. Symptoms not specified, ALT 2
165U/L (normal < 35) initially dropped with treatment to 42U/L and increased 3 weeks after initiation of treatment. ALT 1335U/L with normalization within 2 months after
withdrawal. Intentional 2-day reexposure: ALT 195U/L ALTb < 5N and ALTr = 2ALTb→ positive reexposure.
Compilation of some clinical details and laboratory values for assessment of reported positive reexposure test results in 25 cases with suspected herbal hepatotoxicity by TCM products.
Data are derived from previous reports, which may provide additional details (Teschke, 2014; Teschke et al., 2014b). Unless otherwise stated, reexposure was commonly unintentional.
Criteria for a positive reexposure test result were used as described in Table 4, restricted to criteria provided for the hepatocellular type of liver injury. Accordingly, essential data are
the ALT levels at baseline before reexposure (ALTb), and the ALT levels during reexposure (ALTr). Response to reexposure is positive if ALTr = 2ALTb and ALTb < 5N, with N as the
upper limit of the normal value. Other combinations lead to negative or uninterpretable results. Serum enzyme activities were provided inU/L or multiples of N. Details for calculation of
the R value are presented before (Figure 1). Abbreviation: ALT, alanine aminotransferase; AST, aspartate aminotranferase; N, upper limit of normal; R, ratio; TCM, Traditional Chinese
Medicine.
DILIN method
With use restricted to its own country, the United States DILIN
causality method (Chalasani et al., 2008) does not operate
within the international HILI and DILI mainstream domains,
as opposed to CIOMS (Table 12). The DILIN method may cre-
ate problems even in its homeland when physicians are wait-
ing for conclusions of expert circles at times HILI is unfolding.
Representing a post-clinical, postponed evaluation rather than a
rapid assessment of HILI as a critical disease, the DILIN method
will not gain the same international popularity as its counterpart
CIOMS (Tables 9, 10, 12), also due to other major shortcomings
(Table 13).
Although, various CIOMS criteria (Danan and Bénichou,
1993) have been incorporated in the DILIN method (Rochon
et al., 2008), the DILIN group missed the chance to establish
the fundaments of a newly conceptualized causality method for
DILI and HILI, considering the well known pros ad cons of
CIOMS (García-Cortés et al., 2011; Teschke et al., 2013a, 2014d),
rather than commenting on few shortcomings of CIOMS at the
expense on its own DILIN method (Lewis, 2014). As opposed
to the transparent CIOMS results shown by tables with indi-
vidual scored items (Tables 10, 11) and the applied scale with
actual 15 assumedHILI cases (Table 15), the DILINmethod lacks
both transparency and individual item scorings (Teschke et al.,
2013a, 2014d). Results presented as percentage ranges only and
not given as clearly defined, individually scored items before are
irrelevant. Proving a moderate reliability of their DILIN causality
approach is far from concordance (Rochon et al., 2008; Teschke
et al., 2014d); expert opinion validation therefore seems to be
irrelevant. DILIN should close the present evaluating gap by rec-
ommending physicians in clinical practice to use CIOMS a priori
to improve causality assessment already at origin of clinical data,
while DILIN may later use these CIOMS-based itemized data for
own assessment.
Naranjo scale
Causality assessment of hepatotoxicity cases by the Naranjo scale
(Naranjo et al., 1981) with its known shortcomings is problematic
(Table 13), although favored by the United States Pharmacopeia
(USP) (Mahady et al., 2008) but rejected by the United States
DILIN group (Lewis, 2014) and other groups (García-Cortés
et al., 2011). This scale relates toxic drug reactions to general
pharmacological drug actions rather than specifically to idiosyn-
cratic reactions like hepatotoxicity; it contains drug concentra-
tions and monitoring, dose relationship including decreasing
dose, placebo response, cross-reactivity, and confirmation of the
ADR using unidentified objective evidence, which are irrelevant
for HILI (Naranjo et al., 1981; Teschke and Wolff, 2011; Teschke
and Schulze, 2012). The hepatotoxicity unspecific feature of the
Naranjo scale is unacceptable in suspected HILI cases, its results
are heavily disputed (Liss and Lewis, 2009; Mahady et al., 2008;
Sarma et al., 2008; Teschke, 2010c; Teschke and Wolff, 2011;
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TABLE 10 | CIOMS scale for the hepatocellular type of injury in HILI cases.
Items for hepatocellular injury Score Result
1. TIME TO ONSET FROM THE BEGINNING OF THE HERB
• 5–90 days (rechallenge: 1–15 days) +2
• <5 or >90 days (rechallenge: >15 days) +1
Alternative: Time to onset from cessation
of the herb
• ≤15 days (except for slowly metabolized
chemicals: >15 days)
+1
2. COURSE OF alt AFTER CESSATION OF THE HERB
Percentage difference between ALT peak
and N
• Decrease ≥50% within 8 days +3
• Decrease ≥50% within 30 days +2
• No information or continued drug use 0
• Decrease ≥50% after the 30th day 0
• Decrease <50 % after the 30th day or
recurrent increase
−2
3. RISK FACTORS
• Alcohol use (drinks/d: >2 for woman, >3 for
men)
+1
• Alcohol use (drinks/d: ≤2 for woman, ≤3 for
men)
0
• Age ≥55 years +1
• Age <55 years 0
4. CONCOMITANT HERB(S)/DRUG(S)
• None or no information 0
• Concomitant herb/drug with incompatible
time to onset
0
• Concomitant herb/drug with compatible or
suggestive
• Time to onset −1
• Concomitant herb/drug known as
hepatotoxin and with compatible or
suggestive time to onset
−2
• Concomitant herb/drug with evidence for its
role in this case (positive rechallenge or
validated test)
−3
5. SEARCH FOR NON HERB/DRUG CAUSES
Group I (6 causes) Tick if negative
• Anti-HAV-IgM 2
• HBsAg, anti-HBc-IgM, HBV-DNA 2
• Anti-HCV, HCV-RNA 2
• Hepatobiliary sonography/color Doppler
sonography of liver
vessels/endosonography/CT/MRC
2
• Alcoholism (AST/ ALT ≥ 2) 2
• Acute recent hypotension history (particularly
if underlying heart disease)
2
Group II (6 causes)
• Complications of underlying disease(s) such
as sepsis; autoimmune hepatitis, chronic
hepatitis B or C, primary biliary cholangitis or
sclerosing cholangitis, genetic liver diseases
2
• Infection suggested by PCR and titer change
for
• CMV (anti-CMV-IgM, anti-CMV-IgG) 2
(Continued)
TABLE 10 | Continued
Items for hepatocellular injury Score Result
• EBV (anti-EBV-IgM, anti-EBV-IgG) 2
• HEV (anti-HEV-IgM, anti-HEV-IgG) 2
• HSV (anti-HSV-IgM, anti-HSV-IgG) 2
• VZV (anti-VZV-IgM, anti-VZV-IgG) 2
Evaluation of group I and II
• All causes-groups I and II −- reasonably ruled
out
+2
• The 6 causes of group I ruled out +1
• 5 or 4 causes of group I ruled out 0
• Less than 4 causes of group I ruled out −2
• Non drug or herb cause highly probable −3
6. PREVIOUS INFORMATION ON HEPATOTOXICITY OF THE HERB
• Reaction labeled in the product
characteristics
+2
• Reaction published but unlabeled +1
• Reaction unknown 0
7. RESPONSE TO READMINISTRATION
• Doubling of ALT with the herb alone, provided
ALT below 5N before reexposure
+3
• Doubling of ALT with the herb(s) already given
at the time of first reaction
+1
• Increase of ALT but less than N in the same
conditions as for the first administration
−2
• Other situations 0
Total score for patient
The updated CIOMS scale is derived and modified from a previous report (Teschke et al.,
2014c).The above items specifically refer to the hepatocellular type of injury rather than
to the cholestatic or mixed type (shown in Table 11). Abbreviations: ALT, Alanine amino-
transferase; AST, Aspartate aminotransferase; CIOMS, Council for International Organiza-
tions of Medical Sciences; CMV, Cytomegalovirus; CT, Computer tomography; DILI, Drug
induced liver injury; EBV, Epstein Barr virus; HAV, Hepatitis A virus; HBc, Hepatitis B core;
HBsAg, Hepatitis B antigen; HBV, Hepatitis B virus; HCV, Hepatitis C virus; HEV, Hepatitis
E virus; HILI, Herb induced liver injury; HSV, Herpes simplex virus; MRC, Magnetic res-
onance cholangiography; N, upper limit of the normal range; VZV, Varicella zoster virus.
Total score and resulting causality grading: = 0, excluded; 1–2, unlikely; 3–5, possible;
6–8, probable; ≥9, highly probable.
Teschke et al., 2011d,e; Teschke and Schulze, 2012); this also
pertains to a shortened versionwith only 5 of the original 10 items
(Teschke and Schulze, 2012). Lack of hepatotoxicity specificity of
the Naranjo algorithm was associated with missing definition of
liver ADR, unclear time frame and latency period, undefined time
frame for dechallenge, lacking risk factor definition, insufficient
evaluation of alternative diagnoses, inappropriate assessment of
comedication; and missing definition of a positive rechallenge
test (Naranjo et al., 1981; Teschke and Schulze, 2012). This scale
also was considered insensitive, allowing a possible causality even
in the absence of essential data by virtue of the patient simply
having taken the suspected agent (Liss and Lewis, 2009; Sarma
et al., 2008). The Naranjo scale as modified by USP (Mahady
et al., 2008) did not exclude alternative causes such as idiopathic
autoimmune hepatitis, alcoholic or cardiac hepatopathy, other
preexisting liver diseases, DILI, and drug-induced rhabdomyol-
ysis (Sarma et al., 2008; Teschke, 2014; Teschke et al., 2011d,e). It
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TABLE 11 | CIOMS scale for the cholestatic or mixed type of injury in HILI
cases.
Items for cholestatic or mixed injury Score Result
1. TIME TO ONSET FROM THE BEGINNING OF THE HERB
• 5–90 days (rechallenge: 1–90 days) +2
• < 5 or > 90 days (rechallenge: >90 days) +1
Alternative: Time to onset from cessation of the
herb
• ≤30 days (except for slowly metabolized
chemicals: > 30 days)
+1
2. COURSE OF ALP AFTER CESSATION OF THE HERB
Percentage difference between ALP peak and N
• Decrease ≥50% within 180 days +2
• Decrease <50% within 180 days +1
• No information, persistence, increase, or continued
drug use
0
3. RISK FACTORS
• Alcohol use (drinks/d: >2 for woman, >3 for men)
or pregnancy
+1
• Alcohol use (drinks/d: ≤2 for woman, ≤3 for men) 0
• Age ≥55 years +1
• Age <55 years 0
4. CONCOMITANT HERB(S)/DRUG(S)
• None or no information 0
• Concomitant herb/drug with incompatible time to
onset
0
• Concomitant herb/drug with compatible or
suggestive time to onset
−1
• Concomitant herb/drug known as hepatotoxin and
with compatible or suggestive time to onset
−2
• Concomitant herb/drug with evidence for its role in
this case (positive rechallenge or validated test)
−3
5. SEARCH FOR NON HERB CAUSES
Group I (6 causes) tick if negative
• Anti-HAV-IgM 2
• HBsAg, anti-HBc-IgM, HBV-DNA 2
• Anti-HCV, HCV-RNA 2
• Hepatobiliary sonography / color Doppler
sonography of liver vessels / endosonography /
CT / MRC
2
• Alcoholism (AST/ ALT ≥2) 2
• Acute recent hypotension history (particularly if
underlying heart disease)
2
Group II (6 causes)
• Complications of underlying disease(s) such as
sepsis; autoimmune hepatitis, chronic hepatitis B
or C, primary biliary cholangitis or sclerosing
cholangitis, genetic liver diseases
2
• Infection suggested by PCR and titer change for
CMV (anti-CMV-IgM, anti-CMV-IgG)
2
• EBV (anti-EBV-IgM, anti-EBV-IgG) 2
• HEV (anti-HEV-IgM, anti-HEV-IgG) 2
• HSV (anti-HSV-IgM, anti-HSV-IgG) 2
• VZV (anti-VZV-IgM, anti-VZV-IgG) 2
Evaluation of group I and II
• All causes-groups I and II—reasonably ruled out +2
(Continued)
TABLE 11 | Continued
Items for cholestatic or mixed injury Score Result
• The 6 causes of group I ruled out +1
• 5 or 4 causes of group I ruled out 0
• Less than 4 causes of group I ruled out −2
• Non drug cause highly probable −3
6. PREVIOUS INFORMATION ON HEPATOTOXICITY OF THE HERB
• Reaction labeled in the product characteristics +2
• Reaction published but unlabelled +1
• Reaction unknown 0
7. RESPONSE TO READMINISTRATION
• Doubling of ALP with the herb alone, provided ALP
below 2N before reexposure
+3
• Doubling of ALP with the herbs(s) already given at
the time of first reaction
+1
• Increase of ALP but less than N in the same
conditions as for the first administration
−2
• Other situations 0
Total score for patient
For details see legend to Table 10.
therefore appears that the USP approach (Mahady et al., 2008) is
an invalid tool for causality assessment in suspected HILI, lead-
ing to the conclusion that quality of causality assessment is more
important than quantity of counted cases, not vice versa (Teschke
et al., 2012g). Use of this method has raised concern about judg-
ment validity by the USP regarding cases of hepatotoxicty by
green tea (Liss and Lewis, 2009; Teschke and Schulze, 2012).
WHOmethod
The WHO method in short consists of both the WHO scale
and the global introspection by experts (WHO, 2000b) and
was applied for assessing causality in cases of kava hepatotox-
icity by the WHO (2007a) and of PS hepatotoxicity as erro-
neously assumed by the German regulatory agency BfArM
and the Drug Commission of the German Medical Association
(DCGMA, 2011), but the value of this hepatotoxicity unspe-
cific method was heavily debated (Stammschulte and Gundert-
Remy, 2012; Teschke et al., 2012b,c,d) and judged obsolete before
(Teschke and Wolff, 2011), considering its known shortcomings
(Table 13). In general, global introspection represents a strategy
in evaluating the likelihood of drug causality for adverse reac-
tions (Kramer, 1986). Surprisingly, this method also has never
been validated for any ADRs (Teschke et al., 2012c); as early
as 1986, global introspection by experts has been shown to be
neither reproducible nor valid (Kramer, 1986). Both the ques-
tions and the answers are ambiguous (Teschke and Wolff, 2011).
Specifically, the assessor considers factors that might causally link
one or more drugs to an observed ADR, lists all factors, weighs
their importance, and decides the probability of drug causation
(Kramer, 1986). No specific check list or level of strength is given.
The WHO scale was not validated by a gold standard, is
not quantitative, not specific for hepatotoxicity (WHO, 2000b;
Teschke and Wolff, 2011; Teschke et al., 2012b,c,d, 2013b,e).
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TABLE 12 | Selective compilation of international registries and regulatory agencies, and associated groups applying the CIOMS scale for causality
evaluation in suspected HILI and DILI cases.
Cases Products (n) Country/Region Group/Agency References
DILI Synthetic drugs Spain
Europe
Spanish Group for the Study of the Drug-Induced Liver Disease,
Malaga
Andrade et al., 2004
DILI Synthetic drugs (461) Spain
Europe
Spanish Group for the Study of the Drug-Induced Liver Disease,
Malaga
Andrade et al., 2005
DILI Synthetic drugs (28) Spain
Europe
Spain Hepatotoxicity Registry, Grupo de Estudio Para las
Hepatopatías Asociadas a Medicamentos, Malaga
Andrade et al., 2004
HILIDILI Various herbal TCM (15)
Synthetic drugs (19)
Singapore
Asia
National University of Singapore Wai, 2006
HILI Black cohosh (31) Various countries
Europe
European Medicines Agency EMA, 2007
HILI Herbs (13) Spain
Europe
Spanish Liver Toxicity Registry García-Cortés et al., 2008
HILI Various herbal TCM (159) Korea
Asia
Chungnam National University, Daejeon Kang et al., 2008
DILI Synthetic drugs (80) Serbia
Europe
Medicines and Medical Devices Agency of Serbia, Belgrade Miljkovic et al., 2011
HILI Herbal Polygonum
Multiflorum (25)
Korea
Asia
Gyeongsang National University School of Medicine,
Jinju/Sungkyunkwan University School of Medicine, Changwon
Jung et al., 2011
HILI Various herbal TCM (27) Hong
Kong
Hong Kong Herb-Induced Liver Injury Network (HK-HILIN), Hong
Kong
Chau et al., 2011
DILI Statins (73) Iceland/Sweden
Europe
National University Hospital Reykjvik/ University of Gothenburg/
Swedish Adverse Drug Reactions Advisory Committee (SADRAC)
Björnsson et al., 2012
DILI Various synthetic Drugs Spain
Latin America
Spanish-Latin American Network on drug induced liver Injury, in
progress
Bessone, 2012
HILI Some Herbalife®
products
Various
countries
Various groups Halegoua-De Marzio et al., 2013
HILI Various herbal and dietary
supplements (HDS)
Spain
Europe
Spanish group for the Study of the Drug-Induced Liver Injury Robles-Diaz et al., 2015
Reliability, sensitivity, specificity, positive and negative predictive
values are unknown. Its scope is also limited since it cannot dis-
criminate between a positive and a negative correlation, thereby
stimulating overdiagnosing and overreporting (Teschke et al.,
2013b). The WHO method ignores uncertainties in daily dose,
temporal association, start, duration, and end of herbal use, time
to onset of ADR, and course of liver values after herb discontin-
uation. Insufficiently considered or ignored are comedications,
pre-existing liver diseases, numerous alternative explanations,
and exclusion of virus infections by hepatitis A - C, CMV, EBV,
HSV, and VZV (Teschke et al., 2012b,d). Similarly, case dupli-
cations and retracted cases remained undetected by the WHO
method (Teschke et al., 2012a). Despite these flaws, the WHO
method was used for causality assessment in herbal hepatotox-
icity cases (Elinav et al., 2007; Schoepfer et al., 2007; DCGMA,
2011; Stammschulte and Gundert-Remy, 2012; Teschke et al.,
2012b,d); claimed causality for PS was not confirmed after reeval-
uation in two studies (Teschke et al., 2012b,d).
Other approaches
Other attempts to evaluate causality in assumed HILI cases exist
(Hung et al., 2011), also the ad-hoc assessment (Kaplowitz, 2001),
which was preferentially used for kava cases by the German regu-
latory agency (BfArM, 2002) and in detail disputed subsequently
(Teschke and Wolff, 2011), and the Karch & Lasagna method
applied in some HILI cases of Herbalife R© and considered
obsolete recently (Teschke et al., 2013d), due to known
shortcomings.
Questionable and Lacking Causality
Although causality was firmly established for various herbal
TCM preparations as well as other herbs and herbal products in
reported HILI cases (Tables 1, 2) (Teschke et al., 2011a, 2012a,e,
2014a), causality problems emerged with a few herbs and herbal
preparations as evidenced by some full length published reports
with detailed analyses. Among these are black cohosh with a pos-
sible causality grading in one single HILI case (Teschke, 2010c)
and lacking causality in another study (Naser et al., 2011), kava
with a highly probable causality level in one HILI case con-
firmed by a positive reexposure test result (Teschke et al., 2008a),
and a confirmed causality grading assessed by a positive reexpo-
sure test result for a Herbalife R© product in a single HILI case
(Teschke et al., 2013d); however, CIOMS/RUCAM based causal-
ity for some Herbalife R© products was highly probable in one
patient and probable in six patients, as preliminarily reported in
abstract form without any case details including case data quality
(Halegoua-De Marzio et al., 2013), which was described as poor
and scattered before (Teschke et al., 2013c).
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TABLE 13 | Core elements of the updated CIOMS scale vs. DILIN method.
Items CIOMS DILIN
scale method
Accurate time frame of latency period (score) + 0
Detailed time frame of challenge (score) + 0
Clear time frame of dechallenge (score) + 0
Recurrent ALT or ALP increase (score) + 0
Definition of risk factors (score) + 0
Details to exclude alternative diagnoses (score) + 0
Assessment of HAV, HBV, HCV, HEV (score) + 0
Assessment of CMV, EBV, HSV, VZV (score) + 0
Liver and biliary tract imaging (score) + 0
Color Doppler sonography of liver vessels (score) + 0
Assessment of preexisting diseases (score) + 0
Evaluation of cardiac hepatopathy (score) + 0
Individual score of alternative diagnoses (score) + 0
Qualified score of individual comedication (score) + 0
Prior known hepatotoxicity of the herb (score) + 0
Search for unintended reexposure (score) + 0
Definition of unintended reexposure (score) + 0
Qualified criteria of unintended reexposure (score) + 0
Laboratory criteria for hepatotoxicity + +
Laboratory hepatotoxicity pattern + +
Hepatotoxicity specific method + +
Structured, liver related method + 0
Quantitative, liver related method + 0
Validated method for hepatotoxicity (gold standard) + 0
Adapted and derived from a previous report (Teschke et al., 2013a). Latency period indi-
cates time from herb start to symptoms, alternatively to abnormal liver tests. The symbol+
shows that this item is present and the symbol 0 indicates lack of this item. Abbreviations:
ALT, Alanine aminotransferase; ALP, Alkaline phosphatase; CIOMS, Council for Interna-
tional Organizations of Medical Sciences; CMV, cytomegalovirus; DILIN, Drug-Induced
Liver Injury Network;EBV, Epstein Barr virus; HAV, Hepatitis A virus; HBV, Hepatitis B virus;
HCV, Hepatitis C virus; HEV, Hepatitis E virus; HSV, Herpes simplex virus; VZV, Varicella
zoster virus.
With Ba Jiao Lian (Dysosma pleianthum), this TCM herb was
not further considered as hepatotoxic (Teschke, 2014; Teschke
et al., 2014c, 2015b), since not all diagnostic criteria were fulfilled
for cases of hepatotoxicity by this herb (NIH, 2014c; Teschke,
2014). In detail, after herbal use at recommended doses, the
patients manifested abnormal liver function tests associated with
nausea, vomiting, diarrhea, abdominal pain, thrombocytopenia,
leucopenia, sensory ataxia, altered consciousness and persistent
peripheral tingling or numbness. However, the increase of the
aminotransferases was marginal, with preference of AST rather
than ALT. The AST increase could reflect isolated damage of
the mitochondria around the hepatic central vein or muscular
damage, because of the associated increase of creatine phospho-
kinase, findings not in support for a clinically relevant toxic liver
disease (Teschke, 2014). Evidence against a hepatotoxic poten-
tial was also provided for Jing Tian San Qi (Sedum aizoon) as
another herbal TCM (Teschke, 2014), based on the results of
recent studies showing that in patients with HSOS, the hepato-
toxic PAs in the herbal TCM Tu San Qi (Gynura segetum) were
responsible rather than the misidentified Sedum aizoon lacking
these alkaloids (Dai et al., 2006; Gao et al., 2006, 2012; Wu et al.,
2008; Lin et al., 2011; Wang and Gao, 2014).
Pathogenetic Aspects of HILI
Any HILI case report should describe details to ensure a patho-
genetic case classification, using appropriate criteria that char-
acterize two major forms of HILI (Figure 1). One of these
is named idiosyncratic, the other one intrinsic (Zimmerman,
1999; Teschke et al., 2008a). The idiosyncratic form of injury is
unpredictable and independent of the dose; its metabolic and
immunologic subtypes require special attention in clinical prac-
tice (Figure 1). Conversely, the intrinsic form of liver injury
is predictable and dose dependent (Figure 1). Although, valid
data are lacking, it appears that most HILI cases are of the
idiosyncratic rather than the intrinsic form.
Idiosyncratic Form
As an example, clinical assessment characterized kava hepato-
toxicity as an idiosyncratic liver injury linked to a metabolic
aberration in unusually susceptible humans, providing an over-
all low incidence of kava hepatotoxicity in the normal population
(Teschke et al., 2008a). This rarity of kava hepatotoxicity was also
considered in the recent kava trial and evaluated as a positive
risk/benefit constellation (Court, 2014), opposing previous regu-
latory assumptions to the contrary (BfArM, 2002). In accordance
with other HILI cases of the idiosyncratic form of injury, human
kava hepatotoxicity is not reproducible in experimental animals.
Therefore, results of preclinical assessments with kava in experi-
mental studies showing lack of liver toxicity are not transferrable
to humans with another susceptibility setting and are not suitable
to ensure safe use in humans. Since experimental reproducibility
is missing, the lack of an experimental model prevents analytical
evaluations directed to a proposed molecular mechanism of kava
hepatotoxicity. Regarding human kava hepatotoxicity, character-
istics of the metabolic subtype of the idiosyncratic form of injury
prevail, based on the variable duration of exposure of 1week up
to 12 months, associated with a weak dose dependency (Teschke
et al., 2008a). Overall, most plants are fairly well tolerated by
humans, whether used as normal food, herbal drugs, or HDS.
The pathophysiology of idiosyncratic HILI in humans is dif-
ficult to assess due to lack of experimental reproducibility and
hence missing existence of an experimental animal model of
HILI. There are abundant studies related to effects of herbs on
animals or in vitro cell systems, but uncertainty exists whether
these experimental results are transferable to human idiosyn-
cratic HILI conditions. However, pathogenetic aspects are well
assessable for HILI cases of the intrinsic form, due to avail-
able animal models with experimental hepatotoxicity and the
possibility of transferring their results to human conditions.
Intrinsic Form
Germander (Teucrium chamaedrys) hepatotoxicity is a typi-
cal liver injury of the intrinsic form, since it is dose depen-
dent and reproducible in mice (Larrey and Faure, 2011). Due
to its experimental reproducibility in animals, the molecular
pathogenesis of Germander hepatotoxicity can easily be stud-
ied in experimental hepatotoxicity and transferred to human
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TABLE 14 | Compilation of causality assessment methods used in suspected HILI cases.
Herbs Herbal products Ad hoc (n) WHO (n) CIOMS (n) Naranjo (n) DILIN (n) KL (n) References
Kava 20 BfArM, 2002
Kava 30 Denham et al., 2002
Kava 20 Teschke et al., 2003
Kava 36 Stickel et al., 2003
Kava 80 Schmidt et al., 2005
Greater Celandine 23 BfArM, 2005
Black cohosh 31 EMA, 2007
Herbalife products 12 Elinav et al., 2007
Herbalife products 12 Schoepfer et al., 2007
Kava 26 Teschke et al., 2008a
Black cohosh 30 Mahady et al., 2008
Green tea 34 Sarma et al., 2008[
Black cohosh 4 Teschke and Schwarzenboeck, 2009
Black cohosh 9 Teschke et al., 2009
Kava 31 Teschke, 2010a
Hydroxycut 17 Fong et al., 2010
Black cohosh 22 Teschke et al., 2011e
Greater Celandine 22 Teschke et al., 2011a
Herbalife products 20 Manso et al., 2011
Various herbs 45 Chau et al., 2011
Greater Celandine 21 Teschke et al., 2012e
Pelargonium sidoides 15 Teschke et al., 2012c
Pelargonium sidoides 13 Teschke et al., 2012d
Sum (n) 63 134 275 64 17 20
Sum (percent) 11.0% 23.4% 48.0% 11.2% 3.0% 3.4%
The data are derived from a study evaluating alternative causes in suspected HILI cases (n = 573) (Teschke et al., 2013g). For the 275 CIOMS cases, causality assessment was
performed with the updated CIOMS scale, the original CIOMS scale, or early CIOMS version. Abbreviations: Ad hoc, ad hoc approach; CIOMS, Council for International Organizations
of Medical Sciences scale; DILIN, Drug Induced Liver Injury Network method; KL, Karch & Lasagna method; Naranjo, Naranjo scale; WHO, World Health Organization method.
Germander hepatotoxicity. Germander components are neo-
clerodane diterpenoids that are oxidized by the cytochrome P450
3A isoform into reactive metabolites. These deplete hepatic stores
of glutathione and cytoskeleton associated protein thiols, form
plasma membrane blebs, and cause apoptosis contributing to
liver cell necrosis (Larrey et al., 1992; Larrey and Faure, 2011).
PAs are other good examples for the intrinsic form of liver
injury, which again is clearly dose dependent, thereby pre-
dictable, and hence preventable. For herbs containing PAs, each
consumer of these herbs is at a dose dependent risk developing
HSOS as a specific entity of liver disease (Smith and Desmond,
1993; Sperl et al., 1995; Stillman et al., 1977; Fu et al., 2004).
PA containing plants are probably the most common poisonous
plants affecting not only humans but also livestock and wildlife,
with more than 6.000 plants containing PAs and about 3% of the
world’s flowering plants containing PAs (Fu et al., 2004). Some
of these plants have caused toxic liver disease, recognized as epi-
demics and sometimes primarily assigned to viral hepatitis and
not necessarily to toxic plants (Tandon et al., 1976a,b, 2008).
Human embryotoxicity caused by PAs has been described in a
newborn whose mother drank one cup of a tea containing PAs
per day throughout pregnancy (Roulet et al., 1988; Fu et al., 2004).
Some PA containing plants such as Crotalaria species (Bush
tea, Rattlebox), Ilex paraguarensis (Mate tea), Symphytum species
(Comfrey), Senecio species (Groundsel),Heliotropium species, and
Compositae species (Indian herbs) that caused HILI are tabulated
(Table 2). These herbs also injure cattle and house animals (Fu
et al., 2004) and cause experimental hepatotoxicity in animals
(Lin et al., 2011). PAs can be quantified in the serum of patients
with HSOS (Lin et al., 2011; Larrey and Faure, 2011). The patho-
genesis of PA hepatotoxicity has been elucidated in experimental
studies, which showed the involvement of hepatic microsomal
cytochrome P450 in the activation of PAs (Larrey and Faure,
2011).
Finally, herbal TCM products containing more than 19 g dose
of Radix bupleurimay increase the hepatotoxicity risk (Lee et al.,
2011); this dose dependency was confirmed in experimental ani-
mals and provided insights into some pathogenetic processes (Liu
et al., 2014).
Juristical Considerations
Black Cohosh
Legal aspects of HILI case assessment rarely provide particu-
lar juridical and clinical challenges. Two court decisions merit
attention, one relates to BC and the other one to kava. In 2005, a
report was published representing a case of a 50 year old woman
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TABLE 15 | Preferred documentation as example: Tabulated causality assessment of 15 patients with primarily suspected HILI by Pelargonium sidoides
(PS).
Items Score Patients 1–15
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
1. TIME TO ONSET FROM THE BEGINNING OF THE HERB
• 5–90 days +2 ? +2 +2 +2 +2 +2 +2 +2 ? ?
• <5 or >90 days +1 ? +1 +1 +1 +1 ? ? +1
2. TIME TO ONSET FROM CESSATION OF THE HERB
• ≥15 days +1 ? +1 +1 +1 +1 +1 +1 +1 +1 ? +1 +1 ? ? +1
3. COURSE OF alt AFTER CESSATION OF THE HERB
• Decrease ≥50% within 8 days +3 +3 +3
• Decrease ≥50% within 30 days +2 +2 +2
• No information 0 0 0 0 0 0 0 0 0 0 0
• Decrease ≥50% after the 30th day 0
• Decrease <50% after the 30th day or recurrent
increase
−2 ?
4. RISK FACTOR ETHANOL
• Alcohol use (drinks/d: >2 for woman, >3 for men) +1 ? ?
• No alcohol use (drinks/d: ≤2 for woman, ≤3 for
men)
0 0 0 0 0 0 0 0 0 0 0 0 ? 0
5. RISK FACTOR AGE
• ≥55 years +1 +1 +1 +1
• <55 years 0 0 0 0 0 0 0 0 0 0 0 0 0
6. CONCOMITANT HERB(S)/DRUG(S)
• None or no information 0 0 0 0 0 0 0 0 0 0
• Concomitant herb/drug with incompatible time to
onset
0 0
• Concomitant herb/drug with compatible or
suggestive time to onset
−1 −1
• Concomitant herb/drug known as hepatotoxin
and with compatible or suggestive time to onset
−2 −2 −2 ? −2
• Concomitant herb/drug with evidence for is role in
this case (positive rechallenge or validated test)
−3
7. SEARCH FOR NON HERB/DRUG CAUSES
Group i (6 causes)
• Anti-HAV-IgM – – – –
• Anti-HBc-IgM/HBV-DNA – – – –
• Anti-HCV-IgM/HCV-RNA – – – –
• Hepato-biliary sonography/color Doppler
sonography of liver vessels
– – –
• Alcoholism (AST/ ALT ≥2) – ? – – – – – – – – – –
• Acute recent hypotension history (particularly if
underlying heart disease)
– – – – – – – – – – –
Group II
• Complications of underlying disease(s) such as
sepsis; or: autoimmune hepatitis, chronic hepatitis
B and C, primary biliary cholangitis and
sclerosing cholangitis, genetic liver diseases
? – ? + – + + + – + –
• Infection suggested by PCR and titre change for
CMV (Anti-CMV-IgM/IgG) –
EBV (Anti-EBV-IgM/IgG) –
HSV (Anti-HSV-IgM/IgG)
VZV (Anti-VZV-IgM/IgG)
(Continued)
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TABLE 15 | Continued
Items Score Patients 1–15
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Evaluation of group I and II
• All causes—group I and II—reasonably ruled out +2
• The 6 causes of group I ruled out +1
• 5 or 4 causes of group I ruled out 0
• Less than 4 causes of group I ruled out −2 −2 −2
• Non drug cause highly probable −3 −3 −3 −3 −3 −3 −3 −3 −3 −3 −3 −3 −3 −3
8. PREVIOUS INFORMATION ON HEPATOTOXICITY OF THE HERB
• Reaction labeled in the product characteristics +2 +2 +2 +2 +2 +2 +2 +2 +2 +2 +2 +2 +2 +2 +2 +2
• Reaction published but unlabelled +1
• Reaction unknown 0
9. RESPONSE TO READMINISTRATION
• Doubling of ALT with the herb alone +3
• Doubling of ALT with the herbs/drugs already
given at the time of first reaction
+1
• Increase of ALT but less than N in the same
conditions as for the first administration
−2
• Other situations 0
• Total points for patient 0 +2 −1 +5 +1 +2 +2 +1 +4 0 +2 +5 −1 +1 +1
Preferred documentation of causality assessment using the scale of the updated CIOMS (Council for International Organizations of Medical Sciences), considering the items for the
hepatocellular type of liver injury and the data of a previous report of 15 patients with primarily suspected HILI by Pelargonium sidoides (PS) (Teschke et al., 2012b). In the above
section 6 of concomitant herb(s)/drug(s), the following products were considered: synthetic drugs, dietary supplements including herbal ones, and polyherbal products. In the section
7 (search for non-herb/drug causes), the symbol of—denotes that the obtained result was negative and that of + was positive, whereas lack of a symbol indicates that assessment
was not performed. ALT denotes alanine aminotransferase, AST aspartate aminotransferase, HAV hepatitis A virus, HBc hepatitis B core, HBV hepatitis B virus, HCV hepatitis C virus,
CMV cytomegalovirus, EBV Epstein Barr virus, HSV herpes simplex virus, PCR Polymerase Chain Reaction, VZV varicella zoster virus. Total points/causality: ≤0/excluded; 1–2/unlikely;
3–5/possible; 6–8/probable; ≥9/highly probable.
with fulminant liver failure and liver transplantation in assumed
connection with the use of BC (Levitsky et al., 2005). A prod-
uct liability action was filed by the patient after her recovery
(Nebraska, 2006).
The decision of the judge answered the question whether
in the specific case under discussion sufficient evidence estab-
lishes the herb as a generally or individually specific cause for
the observed liver disease; for black cohosh, both aspects of cau-
sation were denied. General causation refers to the previously
established hepatotoxicity by the same herb, but this was denied
because of lack of convincing data. Specific causation refers to
the case under discussion; this was also refuted on grounds of
conflicting case data, poor case data quality, and numerous con-
founding variables (Nebraska, 2006). Our clinical diagnosis in
this case was herpetic hepatitis and liver disease unrelated to BC
or comedicated drugs, and CIOMS based assessment led to an
excluded causality for both BC and comedicated drugs (Teschke
and Schwarzenboeck, 2009): For this case of BC overdose, con-
clusions for an update of 22.12.2006 were provided (EMA, 2007):
Worst case causality scoring would be possible, if comments of
the expert would not be taken into account; because of the clini-
cal experience of the expert and the requested obligatory causal-
ity in front of an American court, preference is given keeping
the causality at a probable level (EMA, 2007). The conclusions
of EMA are cloudy, difficult to reconcile, and ignore presented
details, since the judge actually excluded both involved experts
from expert testimony as to causation according to Daubert, rule
702 (Nebraska, 2006). As explained in detail, this rule requires
that an expert be qualified to render a testimony on the sub-
ject, and that his testimony be reliable and relevant. None of the
experts obviously met these and other required qualifications.
Following the trial, USP reduced the causality for BC in this
case from a probable to a possible level (Mahady et al., 2008).
An erratum clarified the case conditions (Levitsky et al., 2008).
Our clinical diagnosis in this case was herpetic hepatitis and liver
disease unrelated to BC or comedicated drugs; CIOMS based
assessment led to an excluded causality for both BC and comedi-
cated drugs (Teschke and Schwarzenboeck, 2009). In retrospect,
this court case calls for a thorough transparent documentation of
HILI cases, associated with an unbiased expert opinion.
Kava
Kava was in the focus of another trial in connection with its
marketing withdrawal by the German regulatory agency BfArM
(Schmidt, 2014). Almost 12 years after the German regulatory
agency BfArM issued an intermediate withdrawal of market-
ing authorization for products containing extracts of kava (Piper
methysticum, Piperaceae) root and/or rhizoma (BfArM, 2002),
the case has been reviewed by the German administrative court
in Cologne (Court, 2014). According to the court’s ruling on June
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11, 2014, there was no justification for the ban of kava medic-
inal products issued by the German BfArM (Schmidt, 2014).
The court ruled that based on available evidence, the benefit/risk
ratio of kava medicinal products was confirmed as positive and
must be considered as positive (Court, 2014), with credit given
for previous reports (Schmidt, 2014) assessing causality in cases
of assumed kava hepatotoxicity with the CIOMS scale (Teschke
et al., 2008a, 2010; Teschke and Wolff, 2009; Teschke, 2010a).
Credit was also given (Court, 2014) to the work of others (Sarris
et al., 2013). Their double blind, randomized, placebo controlled
trial was performed with a well defined noble kava drug that is on
the market in Australia, showing both efficacy of kava in patients
treated for their generalized anxiety disorders and lack of overt
adverse reactions (Sarris et al., 2013), confirming kava efficacy
based on a previous Cochrane study (Pittler and Ernst, 2003a). As
a consequence of the court’s ruling, German kava products have
been formally restored to their market status on June 2002. As an
update, BfArM appealed the court’s ruling on June 30, 2014, but
justification for the appeal has not yet been published (Schmidt,
2014). Clearly, the ruling is a major breakthrough, as it strength-
ens the legal certainty and predictability of regulatory decisions
for herbal medicinal product manufacturers in general. It is also a
call for the BfArM and other regulatory agencies to present trans-
parent and appropriate clinical documentations of future HILI
cases to be evaluated by clinically well trained regulatory asses-
sors and external experts in the field, to be more self-critically,
not to dismiss expert views to the contrary a priori, and providing
rather than refuting original HILI case data in anonymous form
to interested requesting scientists to assist in case evaluations.
Essentials of Herbal Product Quality
Herb Authentication and Product Identification
Good quality of herbal drugs and other herbal products is prereq-
uisite for safe human use (Table 16) (Teschke et al., 2013c). How-
ever, shortcomings of herbal products are well documented, both
in herbal TCM and herbal modern medicine. Herbal authenti-
cation was an issue for BC (Sarma et al., 2008; Health Canada,
2010) and various TCM herbs (Haller et al., 2002; Teschke,
2014; Teschke et al., 2014b). There also was considerable debate
whether kava products used by patients with kava hepatotoxic-
ity might have been of poor quality including inappropriate herb
authentication. This led to a comprehensive assessment and a
proposal for a Kava Quality Standardization Code (Teschke and
Lebot, 2011). Actually, several guidelines exist already for Good
Agricultural Practices (GAP) and Good Manufacturing Practices
(GMP), applicable to medicinal plants and herbal medicines to
ensure their product quality (WHO, 2000a, 2003, 2006, 2007b).
Despite these official precautionary recommendations for qual-
ity improvements, batch and product variability is not unusual
(Lebot, 2006; Schmidt, 2007; Teschke and Lebot, 2011; Teschke
et al., 2013c). Violation of GAP or GMP rules also will result in
herbal products that lack efficacy, safety, or both.
When plants are considered for human use as ingredients of a
herbal drug and dietary supplement, a clear definition and iden-
tification of plant family, subfamily, species, subspecies, and vari-
ety is mandatory, best done by a professional classical botanical
description for any herb. Neglect may cause variation in plant
TABLE 16 | Proposal for international harmonization: requirements for
regulatory approved herbal drugs.
Specific international qualification required for regulatory approved herbal
drugs
Good Agricultural Practices
Good Manufacturing Practices
Definition of plant family, subfamily, species, subspecies, and variety
Definition of plant part
Definition of solvents and solubilizers
Lack of impurities, adulterants, and misidentifications
Minimum of batch and product variability
Lack of variety to variety variability
Brand name with details of ingredients, plant parts, batch number, and expiration
date
Manufacturer with address
Regulatory specification of indication of herbal drug use
Daily dose with details of the application form
Maximum duration of herbal drug use
Efficacy of the herbal drug proven by valid RCTs
Description of adverse reactions and their frequency
Information of risk/benefit profile
Internationally approved unified regulatory surveillance
Regulatory harmonization of updated CIOMS scale use to assess causality in
suspected HILI
Placebo controlled randomized double blind clinical trials
Risk/benefit profiles
Data are derived and adapted from a previous report (Teschke et al., 2013c).
family and species, contributing to the overall batch and product
variability. Appropriate information should be provided by the
manufacturers in the consumer’s leaflet, thereby being available
to the physician who suspects liver injury induced by a herbal
product. The leaflet requires the name of the herbal product and
the manufacturer’s address who will provide additional informa-
tion upon request. Therefore, all essential data of herb identifica-
tion and the herbal product should be available before reporting
HILI case details as spontaneous reports to the regulatory agen-
cies or as case report publication. However, pitfalls are evident
already at this stage of case evaluation.
In kava drug hepatotoxicity as an example, herb identifica-
tion problems were evident. The manufacturers did not provide
details on kava variety identification, so this specific informa-
tion was missing in all spontaneous reports and case report pub-
lications (BfArM, 2002; Schmidt, 2007; WHO, 2007a; Teschke
et al., 2008a; Teschke, 2010a,b, 2011). In the South Pacific region
of origin, several hundred kava varieties exist—also called kava
cultivars—and are grouped into noble, medicinal, and Two-Day
varieties (Lebot, 2006; Schmidt, 2007; Teschke and Lebot, 2011;
Teschke et al., 2011b). They differ in their kavalactone compo-
sition and their pleasant and unwanted, possibly toxic effects.
In cases of suspected hepatotoxicity, it remained unclear which
kava variety had to be incriminated. Interestingly, regulatory
approval of kava drugs neither considered different kava vari-
eties nor required respective labeling (BfArM, 2002). Thus, kava
hepatotoxicity remains unexplained.
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Other problems of herb or product identification have been
described in detail in various cases of initially suspected herbal
hepatotoxicity (EMA, 2007; WHO, 2007b; Mahady et al., 2008;
Teschke et al., 2011a,b,d,e). Incomplete herb description com-
plicates accurate association of herbs with liver injury and
allows only general assumptions (Teschke, 2010c; Teschke et al.,
2013e,f). Besides overall herb descriptions, the brand name of
the herbal product has been provided in only a few case reports,
and data for manufacturer, plant part, and extraction solvent
normally was fragmentary (Teschke et al., 2011e, 2013c). For
instance, the rate of undetermined herbal products was 10/16
cases (63%) among published case reports (Teschke et al., 2011e).
This high rate questions the validity of any causality attribu-
tion. Additional problems arise from herbal mixtures, in which
individual ingredients are not specified (Teschke, 2010c; Teschke
et al., 2011d,e). Again, case reports have been published as HILI
even if the patients were not sure whether they used a herbal
product at all (Teschke et al., 2011e).
For GC, case reports assumed causality for hepatotoxicity in
all 21 cases, but details on the GC product were fragmentary
(Teschke et al., 2012e). Out of these 21 cases, seven patients used
a GC monopreparation and four patients a GC polyherbal prod-
uct, brand names and manufacturers were known in only nine
patients. Fears of liability may contribute to the restriction of
detailed product specifications by the authors. On the other hand,
the regulatory agency did not hesitate to provide all relevant data
of GC products from spontaneous cases of GC hepatotoxicity
(Teschke et al., 2011a).
Therefore, unless complete data for herbal identification,
ingredients, and name of the herbal product are provided in each
HILI case, a valid causality assignment is not realistic. Identi-
fication problems are evident also in most HDS providing lit-
tle specific information (Navarro et al., 2014; Robles-Diaz et al.,
2015).
Plant Part Specification
Reports on HILI rarely provide details of the plant part used,
ignoring specific toxic properties attributable to different parts
of a plant. The regulatory recommendation for kava drugs was
to use its peeled rhizome (Teschke and Lebot, 2011). In vari-
ous assumed HILI cases by kava it remained unclear, whether
also unpeeled rhizomes, peeled and unpeeled roots, and/or stem
peelings were used, hampering evaluation of the causative agent
of kava hepatotoxicity (WHO, 2007a; Teschke, 2011). For the
U.S. FDA, peeled kava rhizomes were recommended for kava
supplements (Teschke and Schulze, 2010), and according to the
Australian Therapeutic Goods Administration, the commonly
used medicinal kava products are derived from peeled rhizomes
(Sarris et al., 2009). Plant part specification can be a major reg-
ulatory, agricultural, manufactural, pharmaceutical, and clinical
issue (Teschke and Lebot, 2011).
Solvents and Solubilizers
Herbal drugs and supplements are specified as extracts that are
either water based or prepared from organic solvents like ethanol
or acetone, but regulatory advice is often lacking (Teschke and
Lebot, 2011). Thus, herbal extracts will substantially differ in
their composition depending on the solvent. In addition, numer-
ous solubilizers like macrogol, craspovidon, mentha oil, methyl
acrylic acid polymer and polysorbate polyols may be included
in herbal products to facilitate gastrointestinal uptake (Teschke,
2010b). Therefore, solvents and solubilizers may influence the
composition of chemicals in the herbal product and selectively
affect the bioavailability for the liver as the target organ. These
variations hamper causality attribution in suspected HILI cases,
leading to the recommendation that kava drugs and supplements
should be water based extracts lacking any solvents or solubilizers
(WHO, 2007a; Teschke and Schulze, 2010; Teschke et al., 2011b).
Misidentifications, Impurities, and Adulterants
For herbal product quality, not only plant misidentification but
also contaminants, impurities and adulterants still remain key
problems (Kang-Yum and Oransky, 1992; Espinoza et al., 1995;
Gertner et al., 1995; Huang et al., 1997; Ko, 1998; Ernst, 2002;
Estes et al., 2003; Lebot, 2006; Schmidt, 2007; Seeff, 2007; WHO,
2007b; Mahady et al., 2008; Navarro, 2009; Teschke et al., 2009,
2011c,e; Health Canada, 2010; Larrey and Faure, 2011; Teschke
and Lebot, 2011). Adulterants are not uncommon in herbal TCM
mixtures; they usually consist of synthetic drugs to provide or
fortify product efficacy. Although rarely addressed by analyti-
cal approaches in patients with actually reported HILI, Health
Canada was the only regulatory agency with recently reported
interest in the analytical assessment of herbal products to eval-
uate quality, providing evidence for misidentification of herbs in
some products and presenting results that the accused herb was
not present in the herbal products used by the affected patients
(Health Canada, 2010).
It remains to be established to what extent misidentifications,
impurities, and adulterants are responsible for individual HILI
cases. For instance, possible causality for hepatotoxicity cases of
the herbal TCM mixtures Chaso and Onshido was ascribed to
N-nitroso-fenfluramine, found as adulterant in these slimming
aid products that had been produced in China and sold in Japan
(Adachi et al., 2003). However, there is only little clinical or exper-
imental evidence for a potential hepatotoxicity by this adulterant
(Kanda et al., 2003a,b; Lau et al., 2004). It rather appears that
green tea as ingredient was the causative agent if supplied as
extract (Teschke, 2014).
Misidentification may create major clinical challenges and
harm dramatically the health of consumers, shown for the fol-
lowing cases (Teschke, 2014). Until 2008, overall 41 cases from
China with HSOS, the former HVOD, were reported and causally
attributed to the herbal TCM Jing Tian San Qi (Sedum aizoon,
syn. Stonecrop) (Wu et al., 2008), but causal attribution to Sedum
aizoon was obviously incorrect. Sedum aizoon lacks PAs, and
when applied to experimental animals, HSOS did not eme.g., Lin
et al., 2011, suggesting that a herb containing PAs likely is repon-
sible for the reported cases (Wu et al., 2008). In line with this is
another hepatotoxicity case fromHong Kong withHSOS that ini-
tially also was ascribed to Sedum aizoon, but it turned out to have
been caused by the herbal TCMTu San Qi (Gynura segetum) (Lin
et al., 2011). The name and appearance of Sedum aizoon is sim-
ilar to the one of Gynura segetum, but botanical differentiation
was considered possible for the eye of experts (Lin et al., 2011).
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Comparative studies with both herbs provided clear supportive
evidence for Gynura segetum as culprit for additional cases of
HSOS as compared to Sedum aizoon. Respective studies in mice
showed that Gynura segetum as the PA containing herb but not
Sedum aizoon lacking PAs causes experimental HSOS as assessed
by liver histology results (Lin et al., 2011). In an earlier experi-
mental study, a model of the hepatic veno-occlusive disease was
established by PAs derived from a herb described erronously as
Sedum aizoon (Gao et al., 2006), which again does not contain
PAs (Lin et al., 2011; Gao et al., 2012; Wang and Gao, 2014).
This suggests that the described experimental model (Gao et al.,
2006) was due to the action of a herb containing PAs, most likely
Gynura segetum (Lin et al., 2011; Gao et al., 2012; Wang and
Gao, 2014), rather than to Sedum aizoon lacking PAs (Gao et al.,
2012). Based on these well founded considerations, evidence for
a hepatotoxic potential of Jing Tian San Qi is lacking. The herbal
TCM Sedum aizoon should therefore not be tabulated any more
as hepatotoxic herb, as done until recently (Teschke et al., 2012h).
Gynura segetumwas involved in other cases of herbal misiden-
tification. In two Chinese women, HSOS emerged, which was
induced by PAs of the herbal TCM Gynura segetum (syn. Ju Shan
Qi, Ju Ye San Qi, Shan Chi, San Qi Cao, Shan Chi, Shan Chi) (Dai
et al., 2006). Additional six cases were earlier suspected (Kumana
et al., 1983, 1985); in at least four cases, the culprit was the PA
containing herb Heliotropium lasiocarpum rather than Gynura
segetum (Culvenor et al., 1986).
New Encouraging Steps
Modern medicine is well established on our globe but provides
health facilities only to parts of the population with focus on
patients who can afford the expenditures. Challenges of modern
medicine include management of chronic disorders and orphan
diseases, all at reasonable costs. To achieve this goal, support may
come from herbal medicine, but this will require major efforts at
various levels. Since abundant plants grow in all countries around
the world and are ready to be used for treating human diseases,
herbal medicine may have encouraging perspectives to become
a global player, provided efficacy is proven and associated risks
such as liver toxicity are limited and easily recognizable.
Progress in Developing Valid Diagnostic
Biomarkers
Numerous valid clinical biomarkers exist and enable a firm
diagnosis of most liver diseases unrelated to HILI and DILI,
for instance by assessing specific antibodies of viral hepatitis
(Table 7). New encouraging steps with the development of spe-
cific biomarkers for HILI are discussed (Larrey and Faure, 2011)
in reference to a sensitive and specific assay enabling fthe detec-
tion of a reactive pyrrole-protein adduct in the serum of patients
with HSOS. This disease was attributed to the Tusanqi prepa-
ration made erroneously with Gynura segetum containing PAs
instead with Segetum aizoon lacking PAs (Lin et al., 2011). The
results of this assay show that the patient actually consumed a
herb containing PAs, which are metabolized in the liver to a reac-
tive PAmetabolite, reacting with a protein and forming an adduct
(Larrey and Faure, 2011). However, this assay does not prove
that PAs have caused the hepatotoxicity in this particular patient,
needing supportive evidence in the clinical context. Measuring
herbal toxins or their metabolites in the serum is useful in HILI
cases in a setting of some intoxication, if high levels of the herbal
toxin are expected in the serum due to large amounts of the con-
sumed herb, high cumulative doses, or a prolonged degradation
of the toxic herbal chemical. These conditions apply to HILI cases
of the intrinsic form but not to those of the idiosyncratic form,
which accounts for most HILI cases. For idiosyncratic HILI, sim-
ilar restrictions apply regarding circulating micro-RNA (mRNA),
presently investigated in intrinsic DILI and detectable in fluids
including the serum (Zhou et al., 2013). Omics technologies,
including genomics, proteomics, and metabolomics might well
change but not revolutionize our understanding in the diagnosis
of intrinsic hepatotoxicity (Yang et al., 2012b).
Interest in biomarkers to identify idiosyncratic hepatotoxicity
risks in individuals who use drugs is continuing. For idiosyncratic
DILI, numerous genetic and nongenetic risk factors have been
described as possible biomarkers to predict DILI in some indi-
viduals (Chalasani and Björnsson, 2010), but whether these are
useful to diagnose idiosyncratic HILI is unknown.
Conformed Diagnostic HILI Case Management
At an international level and to provide transparency and compa-
rability, an overall accepted pragmatic stratification of HILI case
assessment and data presentation should be adopted and more
enforced. Sequential case management and presentation should
focus on narrative case details for an overview of clinical fea-
tures. This kind of information is best provided as table, easily
also published even for a high number of cases, as illustrated for
16 HILI cases in a single report (Table 3); this facilitates HILI
characterization caused by a single herb such as GC (Table 4).
Detailed presentation of established criteria of hepatotoxicity def-
inition, differentiation of hepatocellular, cholestatic, and mixed
form of liver injury, and pathogenetic classification should be
mandatory (Figure 1). Information of provided or missed case
details and diagnostic parameters are valuable tools that signify
case data quality and ensure transparency (Table 6). The concept
of a sequential diagnostic approach in suspected HILI cases best
starts with thorough clinical case assessments, subsequently com-
bined with the use of the updated CIOMS scale (Tables 10, 11) as
themainstream tool (Tables 12, 13), and followed by expert opin-
ion, if uncertainty remains. This worldwide applicable strategy
allows transparency and provides a quick basis for final causal-
ity assignments of individual HILI cases by calculating individ-
ual and final scores of individual CIOMS items (Tables 10, 11,
15). This strategy of diagnostic harmonzation is pragmatic, time
and cost saving, and facilitates potential reassessment by other
clinicians, scientists, manufacturers, or regulatory agencies.
International Harmonization of Regulatory Efforts
and Surveillance
Encouraging efforts are reported from the Chinese State Food
and Drug Administration (SFDA), progress is underway to
improve regulatory surveillance of TCM herbal products (Zhang
et al., 2012). In 2012, the SFDA model of safety monitoring and
risk management of TCM drugs was still under exploration,
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with numerous regulatory and clinical issues. These include
information on adulteration and counterfeit TCM drugs and
clarification that except for SFDA approved Chinese and West-
ern compound products, the addition of Western drugs into a
TCM drug formula is illegal. SFDA has established examination
methods and shelf sampling inspection of products in order
to protect the safety of patients. It is not described whether
SFDA proves causality in suspected HILI by TCM and CIOMS
is used in analogy to other international registries and regulatory
agencies (Tables 12, 14).
The regulatory situation of herbal medicines has thoroughly
been evaluated worldwide for most countries of all continents
(WHO, 2005). For herbal supplements, regulatory control varies
among countries and commonly is less stringent or missing,
whereas regulatory approved herbal drugs in Europe are under
strict regulatory surveillance, as are approved synthetic drugs
(EMA, 2014; MHRA, 2014). Regulatory efforts regarding herbal
medicine products should be advanced, aiming at an identical
quality level in all countries. This harmonization is best achieved
by regulatory lifting all HDS to the level of herbal drugs, provided
new regulations are formulated and strictly followed, and preclin-
ical and clinical safety as well as efficacy is proven. Consumers
will benefit from worldwide pharmacovigilance harmonization
and quality control standards of herbal drugs (Table 16), deviced
as previously outlined for kava quality standards (Teschke and
Lebot, 2011).
Sophisticated Evidence Based Trials
China is the country with an extremely high number of published
randomized controlled clinical trials (RCTs) (Wang et al., 2007),
evaluating herbal TCM, but their efficacy has rarely been estab-
lished due to poor study quality (Manheimer et al., 2009; Teschke
et al., 2015a,b). There is increasing awareness that valid evidence
based clinical trials for any herbal treatment should be manda-
tory as shown for kava through a Cochrane analysis (Pittler and
Ernst, 2003a), associated with a robust risk management and bal-
anced risk/benefit profiles (Tang et al., 1999; Wang et al., 2007;
Manheimer et al., 2009; NIH, 2014a,b; Teschke et al., 2015a,b).
For Europe, these trials are commonly required by EMA and
national regulatory agencies for herbal drug approvement; this
established system should be adopted by the WHO for global
harmonization.
Promising New Drug Research and Development
Plants are natural producers of chemical substances, enforcing
great expectations that in the future more synthetic drugs are
developed based on herbal ingredients being effective in human
diseases. In fact, for most of history, herbal medicine was the only
available medicine. It has also been estimated that one third to
one half of currently used drugs were originally derived from
plants (Bent, 2008). Encouraging developments are underway
(Pelkonen et al., 2014), with focus on herbal TCM (Li et al., 2012;
Zhao et al., 2012).
Globalization
With pragmatic modern drug medicine in competition, herbal
medicine should contribute some of its items to a modern type
of drug medicine as part of globalized health care systems at
reasonable costs. On a long run, this approach appears fea-
sible, provided traditional and modern herbal medicine con-
form to the expectations and needs of patients and consumers
(Leonti and Casu, 2013), requiring new steps and improve-
ments based on debated issues outlined above. Globalization of
herbal medicine needs unrestricted exchange of herbal drugs
among all countries. To ensure worldwide high quality, each
herbal medicine should undergo strict regulatory surveillance
and be classified as herbal drug according to internationally
agreed criteria. Among these are strict adherence to GAP and
GMP items, clear definitions of plants, plant parts, and sol-
vents to be used, well defined indications and treatment modal-
ities, proof of evidence based efficacy for the proposed indica-
tions, evaluation of adverse reactions, and positive risk/benefit
profiles (Table 16). Presently, HDS fulfill these criteria only
marginally and need a move to the herbal drug category; other-
wise withdrawal from the market will be the alternative. Concern
exists that presently limited scientific evidence exists to estab-
lish the safety and efficacy of most herbal products (Bent, 2008).
Of the top 10 herbs in the United States, five herbs (ginkgo,
garlic, St. John’s wort, soy, and kava) have scientific evidence
suggesting efficacy, but concerns over safety may temper the
decision to use these products. Consequently, herbal products
are not likely to become an important alternative to standard
medical therapies or a global player, unless there are changes
to the regulation and standardization of these products (Bent,
2008).
Concluding Remarks
Herbal use is common in traditional and modern medicine and
requires more international harmonization to promote herbal
medicine to a global player. In analogy to European regula-
tory settings, herbal medicinal products should be manufac-
tured, marketed, and supervised as regulatory approved drugs
similar to synthetic drugs. Certainly, this requires global con-
sent and major efforts but it could open a global market for
these drugs. International agreement should be reached on
various issues, including best quality of herbal drugs, defini-
tion of indications, and proof of therapeutic efficacy by clin-
ical trials, determination of therapy modalities such as posol-
ogy, and assessment of adverse reactions in line with risk/benefit
profiles. Present issues focus on poor herbal product qual-
ity, lack of proven efficacy, and rare adverse reactions includ-
ing hepatotoxicity.These should be better recognized in the
future by thorough clinical evaluation associated with the
CIOMS scale as the best recognized causality assessing tool
worldwide, possibly followed by expert opinion if uncertainty
remains.
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